FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES Technical Field The invention relates to fused bicycloheterocycle substituted quinuclidine derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. Description of Related Technology Nicotinic acetylcholine receptors (nAChRs) are widely distributed throughout the central (CNS) and peripheral (PNS) nervous systems. Such receptors play an important role in regulating CNS function, particularly by modulating release of a wide range of neuretransmitters, including, but not necessarily limited to acetylcholine, norepinephrine, dopamine, serotonin and GABA. Consequently, nicotinic receptors mediate a very wide range of physiological effects, and have been targeted for therapeutic treatment of disorders relating to cognitive function, learning and memory, neurodegeneration, pain and inflammation, psychosis and sensory gating, mood and emotion, among others. Many subtypes of the nAChR exist in the CNS and periphery. Each subtype . has a different effect on regulating the overall physiological function. Typically, nAChRs are ion channels that are constructed from a pentameric assembly of subunit proteins. At least 12 subunit proteins, α2-α10 and ß2-ß4, have been identified in neuronal tissue. These subunits provide for a great variety of homomeric and heteromeric combinations that account for the diverse receptor subtypes. For example, the predominant receptor that is responsible for high affinity binding of nicotine in brain tissue has composition (α4)2(ß2)3 (the α4ß2 subtype), while another major population of receptors is comprised of the homomeric (0.1)5 (the α7 subtype). Certain compounds, like the plant alkaloid nicotine, interact with all subtypes of the nAChRs, accounting for the profound physiological effects of this compound. While nicotine has been demonstrated to have many beneficial properties, not all of the effects mediated by nicotine are desirable. For example, nicotine exerts gastrointestinal and cardiovascular side effects that interfere at therapeutic doses, and its addictive nature and acute toxicity are well-known. Ligands that are selective for interaction with only certain subtypes of the nAChR offer potential for achieving beneficial therapeutic effects with an improved margin for safety. The α7 nAChRs have been shown to play a significant role in enhancing cognitive function, including aspects of learning, memory and attention (Levin, E.D., J. Neurobiol. 53: 633-640, 2002). For example, α7 nAChRs have been linked to conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, dementia associated with Lewy bodies, dementia associated with Down's syndrome, AIDS dementia, Pick's Disease, as well as cognitive deficits associated with schizophrenia, among other systemic activities. The activity at the α7 nAChRs can be modified or regulated by the administration of α7 nAChR ligands. The ligands can exhibit antagonist, agonist, partial agonist, or inverse agonist properties. Thus, α7 ligands have potential in treatment of various cognitive disorders. Although various classes of compounds demonstrating α7 nAChR-modulating activity exist, it would be beneficial to provide additional compounds demonstrating activity at the α7 nAChRs that can be incorporated into pharmaceutical compositions useful for therapeutic methods. Specifically, it would be beneficial to provide compounds that interact selectively with α7-containing neuronal nAChRs compared to other subtypes. SUMMARY OF THE INVENTION The invention is directed to fused bicycloheterocycle substituted quinuclidine compounds as well as compositions comprising such compounds, and method of using the same. Compounds of the invention have the formula: (Formula Removed)(I) or a pharmaceutically acceptable salt, amide, or prodrug thereof, wherein: n is 0,1, or 2; A is N or N+-CT; X is selected from the group consisting of O, S, and -N(R1)-; Ar1 is a 6-membered aromatic ring containing 0,1,2, 3, or 4 nitrogen atoms, wherein Ar1 is substituted with 0,1, 2, 3, or 4 alkyl groups; Ar2 is a group of the formula: (Formula Removed Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z1, Z2, Z3, and Z4 is C; Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C; Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are independently selected from the group consisting of C and -C(R3c); provided that one of Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 is C and the group of formula (c) is attached to Ar1 through the C atom; Y1 at each occurrence is independently selected from the group consisting of O, S, -N(R2), -C(R3), and -C(R3)(R3a); Y2 is selected from the group consisting of -N(R2), C(=O), -C(R3), and -C(R3)(R3a); Y3 is selected from the group consisting of -N(R2), -C(R3), and -C(R3)(R3a); provided that zero or one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a); wherein when one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a), then Z1, Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar1 through the C atom of -C(R3) of Y1, Y2, or Y3; and also when one of Z1, Z2, Z3, and Z4 is C, then Y1, Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar1 through the C atom of Z1, Z2, Z3, or Z4; Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y1 is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y1 in a group of formula (b) is O, S, -N(R2), or -C(R3)(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y1 in a group of formula (b) is selected from the group consisting of 0, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a); and the group of formula (b) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8; and also wherein when Y1 in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z7, and Z8 are each -C(R3b) and the group of formula (b) is attached to Ar1 through the C atom of-C(R3) of Y1 in the group of formula (b) or through the C atom ofY2aorY3a; R1 and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl; R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6; R3b and R3c at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SON; R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl; R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl. Another aspect of the invention relates to pharmaceutical compositions comprising compounds of the invention. Such compositions can be administered in accordance with a method of the invention, typically as part of a therapeutic regimen for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly a? nAChR activity. Yet another aspect of the invention relates to a method of selectively modulating to nAChR activity, for example a? nAChR activity. The method is useful for treating and/or preventing conditions and disorders related to oc7 nAChR activity modulation in mammals. More particularly, the method is useful for conditions and disorders related to attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CMS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, among other systemic activities. The compounds, compositions comprising the compounds, and methods for treating or preventing conditions and disorders by administering the compounds are further described herein. DETAILED DESCRIPTION OF THE INVENTION Definition of Terms Certain terms as used in the specification are intended to refer to the following definitions, as detailed below. The term "acyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of acyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-l-oxopropyl, 1-oxobutyl, and 1-oxopentyl. The term "acyloxy", as used herein, means an acyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of acyloxy include, but are not limited to, acetyloxy, propionyloxy, and isobutyryloxy. The term "alkenyl", as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens. Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyI, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl. The term "alkoxy", as used herein, means an alkyl group as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy. The term "alkoxyalkoxy", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through another alkoxy group, as defined herein. Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, and methoxymethoxy. The term "alkoxyalkyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2-ethoxyethyl, 2-methoxyethyl, and methoxymethyl. The term "alkoxycarbonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl. The term "alkoxyimino", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through an imino group, as defined herein. Representative examples of alkoxyimino include, but are not limited to, ethoxy(imino)methyl and methoxy(imino)methyl. The term "alkoxysulfonyl", as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl. The term "alkyl", as used herein, means a straight or branched chain hydrocarbon containing from 1 to 6 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl. The term "alkylcarbonyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl. The term "alkylcarbonyloxy", as used herein, means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-bu.tylcarbonyloxy. The term "alkylsulfonyl", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl. The term "alkylthio", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert-butylthio, and hexylthio. The term "alkynyl", as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl. The term "amido", as used herein, means an amino, alkylamino, or dialkylamino group appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of amido include, but are not limited to, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, and ethylmethylaminocarbonyl. The term "aryl", as used herein, means a monocyclic or bicyclic aromatic ring system. Representative examples of aryl include, but are not limited to, phenyl and naphthyl. The aryl groups of this invention are substituted with 0,1, 2, 3,4, or 5 substituents independently selected from acyl, acyloxy, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxyimino, alkoxysulfonyl, alkyl, alkylsulfonyl, alkynyl, amino, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, thioalkoxy, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARB)sulfonyl. The term "arylcarbonyl", as used herein, means an aryl group, as defined herein, or a benzyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of arylcarbonyl include, but are not limited to, phenylcarbonyl and benzylcarbonyl. The term "aryloxycarbonyl", as used herein, means an aryl-O- group, wherein the aryl of aryl-O- is as defined herein, or a benzyoxyl group appended to the parent molecular moiety through a carbonyl group, represented by -C(O)-, as defined herein. Representative examples of aryloxycarbonyl include, but are not limited to, phenoxycarbonyl and benzyloxycarbonyl. The term "arylsulfonyl", as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, (methylaminophenyl)sulfonyl, (dimethylaminophenyl)sulfonyl, and (naphthyl)sulfonyl. The term "carbonyl", as used herein, means a -C(O)- group. The term "carboxy", as used herein, means a -CO2H group. The term "cyano", as used herein, means a -CN group. The term "formyl", as used herein, means a -C(O)H group. The term "halo" or "halogen", as used herein, means -Cl, -Br, -I or -F. The term "haloalkoxy", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of haloalkoxy include, but are not limited to, chloromethoxy, 2-fluoroethoxy, trifluoromethoxy, and pentafluoroethoxy. The term "haloalkyl", as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2-fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fluoropentyl. The term "heteroaryl" means an aromatic five- or six-membered ring containing 1,2,3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. The heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of heteroaryl include, but are not limited to, furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, thienyl, triazinyl, and triazolyl. The heteroaryl groups of the invention are substituted with 0,1,2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysuifonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, -NRARe, (NRAReJalkyl, (NRARe)alkoxy, (NRARB)carbonyl, and (NRARi3)sulfonyl. The term "bicyclic heteroaryl" refers to fused aromatic nine- and ten-membered bicyclic rings containing 1,2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a tautomer thereof. The bicyclic heteroaryl groups are connected to the parent molecular moiety through a carbon or nitrogen atom. Representative examples of bicyclic heteroaryl rings include, but are not limited to, indolyl, benzothiazolyl, benzofuranyl, isoquinolinyl, and quinolinyl. Bicyclic heteroaryl groups of the invention are substituted with 0,1,2, or 3 substituents independently selected from alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl, alkylthio, alkynyl, carboxy, cyano, formyl, haloalkoxy, haloalkyl, halo, hydroxy, hydroxyalkyl, mercapto, nitro, -NRARB, (NRARB)alkyl, (NRARB)alkoxy, (NRARB)carbonyl, and (NRARe)sulfonyl. The term "hydroxy", as used herein, means an -OH group. The term "hydroxyalkyl", as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl. The term "mercapto", as used herein, means a -SH group. The term "nitro", as used herein, means a -N02 group. The term "-NR/JV, as used herein, means two groups, RA and RB, which are appended to the parent molecular moiety through a nitrogen atom. RA and RB are each independently hydrogen, alkyl, alkylcarbonyl, or formyl. Representative examples of-NRARB include, but are not limited to, amino, methylamino, acetylamino, and acetylmethylamino. The term "(NRARB)alkyl", as used herein, means a -NRARs group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of (NRARB)alkyl include, but are not limited to, (amino)methyl, (dimethylamino)methyl, and (ethylamino)methyl. The term "(NRARB)alkoxy", as used herein, means a -NRARB group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein. Representative examples of (NRARB)alkoxy include, but are not limited to, (amino)methoxy, (dimethylamino)methoxy, and (diethylamino)ethoxy. The term "(NRARB)carbonyl", as used herein, means a -NRARs group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. Representative examples of (NRARB)carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, and (ethylmethylamino)carbonyl. The term "(NRARB)sulfonyP1, as used herein, means a -NKARB group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein. Representative examples of (NRARsJsulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, and (ethylmethylamino)sulfonyl. The term "sulfonyl", as used herein, means a -8(0)2- group. The term "thioalkoxy", as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom. Representative examples of thioalkoxy include, but are no limited to, methylthio, ethylthio, and propylthio. Although typically it may be recognized that an asterisk is used to indicate that the exact subunit composition of a receptor is uncertain, for example oc3b4* indicates a receptor that contains the a3 and |34 proteins in combination with other subunits, the term a? as used herein is intended to include receptors wherein the exact subunit composition is both certain and uncertain. For example, as used herein a? includes homomeric (0,1)5 receptors and a7* receptors, which denote a nAChR containing at least one α7 subunit. Compounds of the Invention Compounds of the invention can have the formula (I) as described above. More particularly, compounds of formula (I) can include, but are not limited to, compounds wherein A is N, X is O, and n is 1. More particularly, Ar1 is a group of the formula:(Formula Removed) In a group of formula (b), X1, X2, X3, and X4 are each independently selected from the group consisting of N and -CR10, wherein R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl. Preferably, at least one of X1, X2, X3, and X4 is -CR10, such that group of formula (b) contains 0, 1, 2, or 3 nitrogen atoms. Specific examples of groups for Ar1 are, for example, (Formula Removed Rluand the like, wherein R10 is as defined above for groups of formula (b). Preferred rings for Ar1 are those of the following structures: (Structures Remove wherein R10 is as previously defined for groups of formula (b). A more preferred ring has the structure (Structurre Removed. ' wherein R10 is as previously defined for groups of formula (Specific examples of groups for Ar2 in a compound of formula (I) are, for example, (Formula Removed wherein:Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C and -C(R3b); provided that one of Z1, Z2, Z3, and Z4 is C and formula (ix) is attached to Ar1 through the C atom of Z1 , Z2, Z3, and Z4; Y1 is selected from the group consisting of O, S, and -C(R3)(R3a); Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C; Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8 ; and also wherein when one of Y2a and Y3a is C in the group of formulae (i)-(vii), then Z5, Z6, Z7, and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar1 through the C atom of Y2a or Y3a; and R2, R3, R3a and R3b are as defined for a compound of formula (I). Such rings can be attached to any Ar1 group and are particularly preferred to be attached to a preferred Ar1 group. Preferred rings for Ar2 are those of the following structures: (Structure Removed) wherein R2, Y1, Y2a, Y3a, Z1, Z2, Z3, Z4, Z5, Z6, Z7, and Z8 are as previously defined. Particularly preferred are groups of formula (i). In a preferred group of Ar2, Y2a and Y3a are preferred to be -CR3, wherein R3 is hydrogen, or alkyl, preferably methyl. R3 preferably is hydrogen. The preferred substituent for R2 is hydrogen or methyl, preferably hydrogen. In an embodiment wherein Ar2 is a group of formula (i), it is preferred that Z7 is C and the group of formula (i) is attached to Ar1 through the C atom represented by Z7, such that Ar2 represents an indol-5-yl moiety or a derivative thereof. In such an embodiment it is preferred that A is N, X is O, n is 1 , and Ar1 is a group (Structure Removed) ' wherein R ° is hydrogen or methyl, and particularlyhydrogen. In another embodiment wherein Ar2 is a group of formula (i), it is preferred that Z6 is C and the group of formula (i) is attached to Ar1 through the C atom represented by Z6, such that Ar2 represents an indol-6-yl moiety or a derivative thereof. In such an embodiment it is preferred that A is N, X is O, n is 1, and Ar1 is a group (Structure Removed) wherein R10 is hydrogen or alkyl, particularly methyl, and a preferred group for R10 is hydrogen. In another embodiment wherein Ar2 is a group of formula (i), it is preferred that Z8 is C and the group of formula (i) is attached to Ar1 through the C atom represented by Z8, such that Ar2 represents an indol-4-yl moiety or a derivative thereof. In such an embodiment it is preferred that A is N, X is O, n is 1, and Ar1 is a group (Structure Removed): R10 wherein R10 is hydrogen or alkyl, particularly methyl, and a preferred group for R10 is hydrogen. In another embodiment wherein Ar2 is a group of formula (i), it is preferred that Y3a is C and the group of formula (i) is attached to Ar1 through the C atom represented by Y3a, such that Ar2 represents an indol-3-yl moiety or a derivative thereof. In such an embodiment it is preferred that A is N, X is O, n is 1, and Ar1 is a group R10 (Structure Removed)' wherein R10 is hydrogen or alkyl, particularly methyl, and a preferred group for R10 is hydrogen. In another embodiment wherein Ar2 is a group of formula (I), it is preferred that Y2a is C and the group of formula (i) is attached to Ar1 through the C atom represented by Y2a, such that Ar2 represents an indol-2-yl moiety or a derivative thereof. In such an embodiment it is preferred that A is N, X is O, n is 1, and Ar1 is a group (Structure Removed)• wherein R10 is hydrogen or alkyl, particularly methyl, and a preferred group for R10 is hydrogen. Particularly preferred are compounds wherein Z7 is C and the group of formula (i) is attached to Ar1 through the C atom represented by Z7, such that Ar2 represents an indol-5-yl moiety or a derivative thereof. Also, other specific examples of groups for Ar2 in a compound of formula (I) are, for example, (Formula Removed) wherein Z9, Z10, Z11, Z12, Z13, Z14, Z15, Z16, and R8 are as defined for compounds of formula (I). One embodiment contemplated are compounds of formula (I) wherein A is N; X is 0; and n is 1. Preferred embodiments are, for example, those wherein Ar1 is (Formula Removed) ' wherein R is as previously defined for groups of formula (b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). It is particularly preferred that in a group of formula (i), Z7 is C, such that an indol-5-yl group is attached to Ar1. Other embodiments are, for example, those wherein Ar1 is (Formula Removed) wherein R10 is as previously defined for groups of formula (b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). Yet other embodiments are, for example, those wherein Ar1 is (Formula Removed) R'u wherein R10 is as previously defined for groups of formula (b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). Yet other embodiments are, for example, those wherein Ar1 is (Formula Removed) RIU RIU wherein R10 is as previously defined for groups of formula (b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). Another embodiment are compounds, for example, those wherein Ar1 is (Formula Removed) ' wherein R is as previously defined for groups of formula(b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). Yet another embodiment are compounds, for example, those wherein Ar1 is (Formula Removed)wherein R10 is as previously defined for groups of formula (b), and Ar2 is a group of formula (i), (iv), or (ix), preferably (i). Specific embodiments contemplated as part of the invention include, but are not limited to, compounds of formula (I), as defined, wherein: 3-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indoIe; 4-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1H-indole; 5-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 5-{4-[(3R)-1 -azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1 H-indole; 6-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 2-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 5-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole; 4-[6-(1 -azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1 H-indole; 5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yIoxy]pyrimidin-5-yl}-1H-indole; 4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole; 5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole; 5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1H-indazole; 6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3- benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyI}-4-bromo-1,3-benzothiazol-2- amine; N.[4-(3.methyl-1H-indazol-5-yl)phenyl]quinuclidin-3-amine; (R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (R)-3-[6-(1 -methyl-1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}- dimethyl-amine; (R)-3-[6-(1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane 1 -oxide; 6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2- ylarnine; (3R)-3-[6-(3-bromo-1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; 5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2- one; 5-{6-[(3R)-1 -oxy-1 -aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- indol-2-one; 5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- benzoimidazol-2-one; (R)-3-[6-(1 H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane;(S)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane; (3R)-3-[5-(1 H-indol-4-yl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 1 - oxide; (3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane; (3R)-3-[5-(2-methyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (R)-5-[2-(1-aza-bicycIo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one; (R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazole; 3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (R)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (S)-3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (3R)-3-(6-benzo[b]thiophen-5-yl-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; (3R)-3-[6-(1H-indol-6-yl)-pyridazin-3-yloxy]-1-aza-bicycIo[2.2.2]octane; (3R)-3-(6-benzo[1,2,5]oxadiazol-5-yl-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; 6-{6-[(3R)-(1-aza-bicyclo[2.2.2]oct-3-yl)oxy]-pyridazin-3-yl}-chromen-4-one; (3f?)-3-[6-(2-chloro-1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; (3R)-3-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza bicyclo[2.2.2]octane; (3R)-3-[6-(1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; and (3S)-3-[6-(1H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; or pharmaceutically acceptable salts, amides, and prodrugs thereof. Preferred compounds for the invention are: 5-{6-[(3R)-1 -azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1H-indole; 4-{2-[(3R)-1 -azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine; (R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; (R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}-dimethyl-amine; 5-{6-[(3R)-1 -oxy-1 -aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- indol-2-one; 5-{6-[(3S)-1 -azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indo!e or (S)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; and (R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane; or pharmaceutically acceptable salts, amides, and prodrugs thereof. A more preferred compound of the invention is 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl)-1H-indole. Compound names are assigned by using AuioNOM naming software, which is provided by MDL Information Systems GmbH (formerly known as Beilstein Informationssysteme) of Frankfurt, Germany, and is part of the CHEMDRAW® ULTRA v. 6.0.2 software suite. Compounds of the invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are "R" or "S" depending on the configuration of substituents around the chiral element. The terms "R" and "S" used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976,45:13-30. The invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers. Individual stereoisomers of compounds of the invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and optional liberation of the optically pure product from the auxiliary as described in Furniss, Hannaford, Smith, and Tatchell, "Vogel's Textbook of Practical Organic Chemistry", 5th edition (1989), Longman Scientific & Technical, Essex CM20 2JE, England, or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns or (3) fractional recrystallization methods. Compounds of the invention demonstrate beneficial binding at -1 H-indole fumarate The product of Example 12A (76 mg, 0.24 mmol) was treated with fumaric acid (29 mg, 0.25 mmol) in EtOAc/EtOH (v. 1:1,4 ml) at ambient temperature for 10 hours. The title compound was obtained as solid (94.6 mg, yield, 90%). 1H NMR (300 MHz, CD3OD) 6 1.88-2.21 (m, 3H), 2.33-2.48 (m, 1H), 2.59-2.66 (m, 1H), 3.22-3.50 (m, 5H), 3.84-3.95 (m, 1H), 5.41-5.49 (m, 1H), 6.55 (dd, J=3.4,1.0 Hz, 1H), 6.68 (s, 2H), 7.11 (dd, J=7.5,1.0 Hz, 1H), 7.24 (t, J= 8.1 Hz, 1H), 7.36 (d, J=3.1 Hz, 1H), 7.48 (dt, J=8.1, 0.7 Hz, 1H), 8.89 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Anal. Calculated for C19H20N4O.C4H4O4: C, 63.29; H, 5.54; N, 12.84. Found: C, 62.95; H, 5.85; N, 12.61. Example 13 5-{2-[(3S)-1-Azabicvclo[2.2.2]oct-3-yloxy]pvrimidin-5-yl}-1H-indole Example 13A (3R)-1 -Azabicvclo[2.2.2]oct-3-vl benzoate (L)-tartrate (+/-)-3-Quinuclidinol benzoate (Sigma, 17.9 g, 77.5 mmol) was treated with L-tartaric acid (Aldrich, 99% ee, 11.63 g, 77.5 mmol) in EtOH (80%, 222 ml) at ambient temperature for 1 week. The white solid was filtered off and dried under reduced pressure. 6.5 g of 3-(R)-quinuclidinol benzoate • (L)-tartrate was obtained with ~80% ee (assayed by HPLC. HPLC conditions: chiralpak AD column 25cmX4mm ID. solvent, EtOH : hexanes = 15 : 85. flow rate, 1 mL/min. uv, 220 nm. Retention time: (S)-3-quinuclidinol benzoate, 7.87 min; (R)-3-quinuclidinol benzoate 13.3 min.) Recrystallization of the above solid in EtOH (80%, 35 ml) gave the title product (4.5 g , yield, 15%, >98% ee). MS (DCI/NH3) m/z 232 (M+H)4. Example 13B f3R)-Quinuclidin-3-ol The product of the Example 13A (4.5 g, 11.8 mmol) was treated with Hydrolysis was NaOH (15%, 40 ml) MeOH (40 mL)at 50°C for 10h. The methanol was removed under reduced pressure and the residue was extracted with chloroform (4 x 80 ml). The extracts were combined and dried over MgSO4 (anhydrous). The drying agents were filtered off and the filtrate was concentrated to give the title product as white solid (1.35 g, yield, .90%). MS (DCI/NH3) m/z 128 (M+H)*. Example 13C (3S)-1-Azabicvclo[2.2.2]oct-3-vl benzoate (D)tartrate The mother liquid of Example 13A was combined and concentrated under reduced pressure. The residue was then treated with NaOH (1 N, 50 ml) at room temperature for 30 min. It was extracted with chloroform (3 x mL) The extracts were combined and dried (MgS04). The drying agents were filtered off. The filtrates was concentrated to give 3-quinuclidinol benzoate (15.25 g, 66 mmol) It was then treated with (Dftartaric acid (Aldrich, 97%ee, 9.9 g, 66 mmol,) in EtOH (80%, 190 ml) at room temperature for 3 days according to the procedure of Example 1 A. The title product was obtained (7.0 g, yield, 28%, 92.3% ee). Example 13D (3S)Quinuclidin-3-ol The product of Example 13C (7.0 g, 18.4 mmol) was treated with NaOH (aqueous) according to the procedure of Example 1B. The title product was obtained as white solid (2.0 g, yield, 86% ) MS (DCI/NH3) m/z 128 (M+H)+. Example 13E (3S)-3-[(5-Bromopyrimidin-2-vltoxv1auinuclidine The product of Example 13D (508 mg, 4 mmol) was coupled with 2-iodo-5-bromo-pyrimidine (1.42 g, 5 mmol) according to the procedure of Example 7A.The title compound was purified by chromatography (SiO2, CHbCb: MeOH : NH3-H2O, 90:10:1, Rf. 0.20) as solid (780 mg, yields, 69%)as a solid. 1H NMR (300 MHz, CD3OD) 5 1.47-1.61 (m, 1H), 1.63-1.90 (m, 2H), 1.96-2.12 (m, 1H), 2.19-2.27 (m, 1H), 2.73-3.03 (m, 5H), 3.33-3.45 (m, 1H), 5.05-5.14 (m, 1H), 8.64 (s, 2H) ppm. MS (DCI/NH3): 284 (M+H)+ 286 (M+H)+. Example 13F 5-{2-[(3S)1-Azabicvclo[2.2.21oct-3-yloxy]pvrimidin-5-yl}-1H-indole The product of Example13E (283 mg, 1 mmol) was coupled with 5-indolylboronic acid (193 mg, 1.2 mmol) according to the procedure of Example 3A, The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 urn, 40 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (120 mg, yield, 38%). 1H NMR (300 MHz, CD3OD) 6 1.50-1.63 (m, 1H), 1.66-1.92 (m, 2H), 2.03-2.18 (m, 1H), 2.24-2.32 (m, 1H), 2.75-3.07 (m, 5H), 3.38-3.49 (m, 1H), 5.13-5.21 (m, 1H), 6.53 (dd, J=3.0, 0.7 Hz, 1H), 7.30 (d, J=3.4 Hz, 1H), 7.35 (dd, J=8.5, 1.7 Hz, 1H), 7.51 (dt, J=9.2, 0.7 Hz, 1H), 7.80 (dd, J=1.7, 0.7 Hz, 1H), 8.81 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)+. Example 13G 5-{2-[(3S)-1 -Azabicvclo[2.2.2]oct-3-vloxvlDvrimidin-5-yl}-1 H-indole hemifumarate The product of Example 13F (120mg, 0.38 mmol) was treated with fumaric acid (44 mg, 0.38 mmol) in EtOAc/EtOH (v. 1:1,10 mL). The title compound was obtained as solid (123 mg, yield, 84%). 1H NMR (300 MHz, CD3OD) 6 1.75-2.13 (m, 3H), 2.22-2.37 (m, 1H), 2.46-2.54 (m, 1H), 3.03-3.45 (m, 5H), 3.68-3.79 (m, 1H), 5.30-5.38 (m, 1H), 6.52 (dd, J=3.1,1.1 Hz, 1H), 6.67 (s, 1.2H), 7.30 (d, J=3.1 Hz, 1H), 7.35 (dd, J=8.5, 1.7 Hz, 1H), 7.51 (dt, J= 8.5, 0.7 Hz, 1H), 7.80 (dd, J=1.7, 0.7 Hz, 1H), 8.82 (s, 2H) ppm. MS (DCI/NH3): m/z 321 (M+H)*. Anal. Calculated for Ci9H2oN4O-0.6 C4H404: C, 65.90; H, 5.79; N, 14.36. Found: C, 65.62; H, 5.76; N, 14.40. Example 14 5-[4-( 1 -Azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methvl-1 H-indazole trifluoroacetate The product of Example 1A (200 mg, 0.61 mmol) was coupled with t-butyl-(3-methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, 294 mg, 1 mmol) according to the procedure of Example 2B. The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 urn, 40 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min. flow rate, 75 ml_/min., uv, 250 nm) as solid (70 mg, yield, 26%). 1H NMR (300 MHz, CD3OD) 6 1.85-2.13 (m, 3H), 2.22-2.37 (m, 1H), 2.46-2.50 (m, 1H), 2.58 (s, 3H), 3.23-3.45 (m, 5H), 3.78-3.86 (m, 1H), 4.90-5.00 (m, 1H), 7.07 (dt, J=8.8, 2.0 Hz, 2H), 7.50 (d, J=8.8 Hz, 1H), 7.61-7.68 (m, 3H), 7.85 (s, 1H) ppm. MS (DCI/NH3): m/z 334 (M+H)+. Anal. Calculated for C21H23N30-1.0 CF3CO2H-0.5 H20: C, 60.52; H, 5.52; N, 9.21. Found: C, 60.79; H, 5.39; N, 9.17. Example 15 6-f4-(1-Azabicvclo[2.2.2]oct-3-vloxy)phenyl]-1.3-benzothiazol-2-amine Example 15A 3-[(4'-Nitro-1.1'-biphenvl-4-vl)oxy]quinuclidine 3-Quinuclldinol (Aldrich, 0.51 g, 4 mmol) was coupled with 4'-nitro-1,1'-biphenyl-4-ol (TCI, 0.43 g, 2 mmol) with DIAD (di-isopropyl azadicarboxylate, .Aldrich, 0.81 g, 4 mmol) and Ph3P (Aldrich, 1.04 g, 4 mmol) in THF (anhydrous, Aldrich, 40 ml_) at ambient temperature for two days. The reaction mixture was concentrated. The title product was purified by chromatography (SiO2, CH2Cl2: MeOH : NH3-H2O, 90:10:1, Rf. 0.20) as solid (400 mg, yield, 62%). 1H NMR (300 MHz, CD3OD) 8 1.45-1.57 (m, 1H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1H), 2.17-2.24 (m, 1H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1H), 4.56-4.64 (m, 1H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J=8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)*. Example 15B 4'-(1-Azabicvclor2.2.21oct-3-yloxy)-1.1'-biphenvl-4-amine The product of Example 15A (300 mg, 0.92 mmol) was treated with Pd/C (Aldrich, wt.10%, 30 mg) in methanol (20 ml) under H2 at ambient temperature for 30 min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (200 mg, yield, 74%). 1H NMR (300 MHz, CD3OD) 5 1.44-1.58 (m, 1H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1H), 2.15-2.23 (m, 1H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1H), 4.50-4.58 (m, 1H), 6.77 (dt, J= 8.8, 2.5 Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt.J-9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+. Example 15C 6-r4-(1-Azabicvclor2.2.21oct-3-yloxv)phenyl]-1.3-benzothiazol-2-amine The product of Example 15B (200 mg, 0.68 mmol) and KSCN (Aldrich, 140 mg, 1.52 mmol) were dissolved in HOAc (5 ml). Bromine [Aldrich, 99%, 40 µL 0.76 mmol, in HOAc (1 ml) was added slowly to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 1 h. and then quenched with aqueous NaOH (10%, 20 mL) at 5-10 °C. It was then extracted with CHCI3/PrOH (v. 10 :1, 2 x 50 ml). The extracts were combined and concentrated under reduced pressure. The title compound was purified by chromatography (Si02, CH2Cl2. MeOH; :NH3-H2O,, 90;10:1, Rf. 0.10) as solid (140 mg, yield, 59%). 1H NMR (300 MHz, CD3OD) 5 1O.27-1.37 (m, 1H), 1.51-1.72 (m, 2H), 1.79-1.88 (m, 1H), 2.02-2.07 (m, 1H), 2.51-2.84 (m, 5H), 3.21-3.39 (m, 1H), 4.45-4.52 (m, 1H), 6.97(d, J=8.8 Hz, 2H), 7.35 (d, J=8.5 Hz, 7.45 (dd, J=8.5, 2.1 Hz, 1H), 7.55 (d, J=8.5, 2H), 7.90 (d, J=2.0 Hz, 1H) ppm. MS (DCI/NH3) m/z 352 (M+H)*. Example 15D 6-[4-(1-Azabicvclo[2.2.2]oct-3-yloxy)phenyl]-1.3-benzothiazol-2-amine bistrifluoroacetate The product of Example 15C (140 mg, 0.4 mmol) was treated with trifluroacetic acid (Aldrich, 99%, 114 mg, 80 ML, 1 mmol) in 'PrOH (5 ml) at ambient temperature for 15 h. The title compound was obtained as solid (90 mg, yield, 39%). 1H NMR (300 MHz, DMSO-D6) 5 1.75-2.16 (m, 3H), 2.30-2.52 (m, 2H), 3.03-3.45 (m, 5H), 3.75-3.82 (m, 1H), 4.78-4.85 (m, 1H), 7.05 (d, J=8.8 Hz, 2H), 7.38 (d, J=8.5 Hz, 1H), 7.50 (dd, J=8.5, 2.1 Hz, 1H), 7.62 (d, J=8.8 Hz, 2H), 7.76 [s(broad.), 2H], 7.96 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 352 (M+H)+. Anal. Calculated for C2oH2iN3OS-2.08 CF3CO2H C, 49.30; H, 3.95; N, 7.14. Found: C, 49.70; H, 3.42; N, 7.03. Example 16 6-(4-[(3R)-1-Azabicvclof2.2.21oct-3-yloxy]phenyl}-1.3-benzothiazol-2-amine Example 16A (3RV3-r(4'-Nitro-1.1'-biphenyl-4-yl)oxv1quinuclidine The product of Example 4A (1.28 g, 10 mmol) was coupled with 4-iodo-4'-nitro-biphenyl (TCI, 1.62 g, 5 mmol) according to the procedure of Example 1A. The title product was purified by chromatography (SiO2, CH2CI2: MeOH : NH3-H2O, 90:10:1, Rf. 0.20) as solid (930 mg, yield, 57%). 1H NMR (300 MHz , CD3OD) 8 1.45-1.57 (m, 1H), 1.63-1.91 (m, 2H), 1.97-2.12 (m, 1H), 2.17-2.24 (m, 1H), 2.66-3.00 (m, 5H), 3.30-3.41 (m, 1 H), 4.56-4.64 (m, 1 H), 7.05 (dt, J=8.8, 2.6 Hz, 2H), 7.68 (dt, J=9.2, 2.6 Hz, 2H), 7.82 (dt, J'8.8, 2.7 Hz, 2H), 8.28 (dt, J=8.8, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 325 (M+H)*. Example 16B + 4'-[(3R)-1 -Azabicvclo[2.2.2]oct-3-yloxy]-1.1 '-biphenyl-4-amine The product of Example 16A (580 mg, 1.79 mmol) was treated with Pd/C (Aldrich, wt.10%, 100 mg) in ethanol (50 mL) under H2 at ambient temperature for 30 min. After the reaction was complete, the catalyst was removed through a short column of diatomaceous earth. The filtrate was concentrated under reduced pressure to provide the title compound (520 mg, yield, 99%). 1H NMR (300 MHz, CD3OD) 5 1.44-1.58 (m, 1H), 1.63-1.89 (m, 2H), 1.99-2.13 (m, 1H), 2.15-2.23 (m, 1H), 2.72-3.04 (m, 5H), 3.29-3.39 (m, 1H), 4.50-4.58 (m, 1H), 6.77 (dt, J= 8.8, 2.5 Hz, 2H), 6.91 (dt, J=8.8, 2.4 Hz, 2H), 7.32 (dt, J= 8.5, 2.5 Hz, 2H), 7.43 (dt,J= 9.2, 2.8 Hz, 2H) ppm. MS (DCI/NH3) m/z 295 (M+H)+. Example 16C 6-(4-[(3R)1-Azabicvclor2.2.2]oct-3-yloxy]phenvl}-1.3-benzothiazol-2-amine triftrifluoroacetate) The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 ml). Bromine [Aldrich, 99%, 47 µL, 0.90 mmol, in HOAc (1 mL)] was slowly added to the above solution over 5 min. The mixture was stirred at ambient temperature for additional 2 hours, and quenched with aqueous NaOH (10%, 20 ml) at 5-10 °C. It was then extracted with CHCI3/'PrOH (v. 10 :1,2 x 50 ml). The extracts were combined and concentrated under reduced pressure. The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 pm, 40 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (150 mg, yield, 19%). 1H NMR (300 MHz, DMSO-D6) 5 1.84 - 2.20 (m, 3 H), 2.22 -2.44 (m, 1 H), 2.47 - 2.69 (m, 1 H), 3.32 - 3.51 (m, 5 H), 3.74 - 3.93 (m, 1 H), 4.89 -5.02 (m, 1 H), 7.01 - 7.15 (m, 2 H), 7.53 (d, J=8.5 Hz, 1 H), 7.59 - 7.66 (m, 2 H), 7.69 (dd, v/=8.5,1.7 Hz, 1 H), 7.98 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3): m/z 352 (M+H)+. Anal. Calculated for C20H21N3OS-3.00 CF3CO2H C, 45.03; H, 3.49; N, 6.06. Found: C, 44.70; H, 3.42; N, 6.00. Example 176-{4-[(3R)-1-Azabicycio[2.2.2]oct-3-yloxy]Dhenyl}-4-thiocvanato-1.3-benzothiazol-2- amine trifluoroacetate The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 ml). Bromine [Aldrich, 99%, 47 µL, 0.90 mmol, in HOAc (1 ml)] was added slowly to the above solution over 5 min. according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 urn, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (55 mg, yield, 12%). 1H NMR (300 MHz, MeOH-D4) 6 1.79 - 2.24 (m, 3 H), 2.22 - 2.44 (m, 1 H), 2.46 - 2.65 (m,, 1 H), 3.30 - 3.52 (m, 5 H), 3.74 - 3.90 (m, 1 H), 4.93 (dd, J=9.2, 5.1 Hz, 1 H), 6.96 - 7.23 (m, 2 H) 7.48 -7.70 (m, 3 H) 7.88 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 409 (M+H)+. Example 18 6-{4-[(3R)-1-Azabicvclo[2.2.2]oct-3-yloxylphenyl}-4-bromo-1.3-benzothiazol-2-amine bisftrifluoroacetate) The product of Example 16B (250 mg, 0.85 mmol) and KSCN (Aldrich, 165 mg, 1.70 mmol) were dissolved in HOAc (5 ml). Bromine [Aldrich, 99%, 47 µL, 0.90 mmol, in HOAc (1 ml) was added slowly to the above solution over 5 min. according to procedure of Example 16C. The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 urn, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50 mg, yield, 9%). 1H NMR (300 MHz, MeOH-D4) 6 1.78 - 2.21 (m, 3 H), 2.23 - 2.44 (m, 1 H), 2.47 - 2.63 (m, 1 H), 3.23 - 3.53 (m, 5 H), 3.66 - 3.97 (m, 1 H), 4.88 - 5.03 (m, 1 H), 6.96 - 7.22 (m, 2 H), 7.52 - 7.65 (m, 2 H), 7.68 (d, J=1.7 Hz, 1 H), 7.82 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): m/z 430 (M+H)+, 432 (M+H)*. Anal. Calculated for C2oH2oBrN3OS-2.00 CF3CO2H C, 43.78; H, 3.37; N, 6.38. Found: C, 44.70; H, 3.42; N, 6.32. Example 19 N-[4-(3-Methyl-1H-indazol-5-yl)bhenvnauinuclidin-3-amine Example 19A N-(4-lodophenvnauinuclidin-3-amine 3-Quinuclidinone hydrochloride (Aldrich, 3.22 g, 20 mmol) was treated with 4-iodo-aniline (Aldrich, 2.19 g, 10 mmol), Na2SO4 (anhydrous, Aldrich, 7.40 g, 50 mmol) and NaBH(OAc)3 (Aldrich, 3.16 g, 15 mmol) in HOAc (25 mL) at ambient temperature for 15 h. After the reaction was complete, the reaction mixture was slowly poured into a flask containing 75 mL of saturated NaHCO3 and stirred for 20 min. It was then extracted with EtOAc (3 x 100 mL). The extracts were combined and washed with brine (2 x 20 mL). The organic solution was concentrated under reduced pressure and the title compound was purified by chromatography (SiO2, CH2CI2: MeOH : NH3-H2O, 90:10:2, Rf. 0.10) as oil (3.24 g, yield, 98%). 1H NMR (300 MHz, CD3OD.) 8 1.70-1.81 (m, 1H), 1.93-2.04 (m, 2H), 2.08-2.24 (m, 2H), 2.89 (ddd, J=12.9, 5.1, 2.7 Hz, 1H), 3.12-3.28 (m, 4H), 3.64 (ddd, J=12.9, 9.5, 2.4 Hz, 1H), 3.79-3.85 (m, 1H), 6.46 (dt, J=9.0, 2.7 Hz, 2H), 7.39 (dt, J=9.1, 2.7 Hz, 2H) ppm. MS (DCI/NH3) m/z 329 (M+H)+. Example 19B N-[4-(3-Methyl-1H-indazol-5-vnphenyl]quinuclidin-3-aminetrifluoroacetate The product of Example 19A (200 mg, 0.61 mmol) was coupled with t-Butyl-(3-Methyl-5-trimethylstannanyl-indazole)-1-carboxylate (ref. US 2003199511, 294 mg, 1 mmol) according to the procedure of Example 2B. The title product was purified by preparative HPLC (Gilson, column, Symmetry® C-8 7 urn, 40 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 ml_/min., uv, 250 nm) as solid (28 mg, yield, 10%). 1H NMR (300 MHz, CD3OD) 5 1.85-1.96 (m, 1H), 2.08-2.15 (m, 2H), 2.24-2.40 (m, 2H), 2.59 (s, 3H), 3.02-3.15 (m, 1H), 3.20-3.45 (m, 4H), 3.78-3.88 (m, 1H), 3.98-4.06 (m, 1H), 6.77 (dt, J=8.8, 2.0 Hz, 2H), 7.46-7.52 (m, 3H), 7.59 (dd, J=8.9, 1.6 Hz, 1H), 7.78 (s, 1H) ppm. MS (DCI/NH3): m/z 333 (M+H)+. Anal. Calculated for C21H24N4-1.25 CF3CO2H: C, 59.43; H, 5.36; N, 11.80. Found: C, 59.20; H, 4.96; N, 11.62. Example 20 (R)-3-{6-(3-Methyl-'1H-inaazol-5-yl)-pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octanefumarate Example 20A 3-Methvl-5-trimethvlstannanyl-indazole-1-carboxylic acid tert-butyl ester 5-Bromo-3-methyl-indazole-1-carboxylic acid tert-butyl ester (3.0 g, 9.6 mmol) was coupled with hexamethylditin (Aldrich, 4.73 g, 14.4 mmol) catalyzed by Pd(PPh3)4 (Aldrich, 1.1 g, 0.96 mmol) in anhydrous toluene (Aldrich, 50 ml) at 115 °C (oil bath) under N2 for 2 h. After the reaction went to completion, the black reaction mixture was cooled down to ambient temperature and directly loaded to a flash silica gel column (5-30% EtOAc in hexane) for purification to provide the title compound (3.06 g, 80%). 1H NMR (MeOH-d4, 300 MHz) 0.23 - 0.45 (m, 9 H) 1.71 (s, 9 H) 2.59 (s, 3 H) 7.67 (d, J=8.1 Hz, 1 H) 7.87 (s, 1 H) 8.06 (d, J=8.5 Hz, 1 H) ppm. MS (DCI/NHa) m/z 397(M+H)+. Example 20B (R)-3-[6-(3-Methvl-1H-indazol-5-yl)-pvridazin-3-yloxy]-1-aza-bicvclor2.2.2]octane The product of Example 9A (120 mg, 0.5 mmol) was coupled with the product of Example 20A (278 mg, 0.7 mmol) under the catalysis of by Pd2(dba)3 (Aldrich, 24 mg, 0.025 mmol) and ((Bu3P)2 Pd (Strem Chemicals, 26 mg, 0.05 mmol) with CsF (Strem Chemicals, 152 mg, 1 mmol) in dioxane (10 ml) at 80°C under N2 for 16 hours. After the reaction went to completion, it was diluted with EtOAc (50 ml) and washed with brine (2x10 ml). The organic solution was concentrated under vacuum and the residue was treated with TFA (1 mL) in CH2CI2 (5 ml) at ambient temperature for 2 hours. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 Mm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HC03,0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 ml/mm., uv, 250 nm) as solid (68 mg, 41%). 1H NMR (MeOH-D4, 300 MHz) 1.50 - 1.66 (m, 1 H) 1.70 -1.94 (m, 2 H) 2.01 - 2.15 (m, 1 H) 2.29 - 2.37 (m, 1 H) 2.62 (s, 3 H) 2.81 - 3.04 (m, 5 H) 3.44 - 3.56 (m, 1 H) 5.28 - 5.36 (m, 1 H) 7.28 (d, J=9.2 Hz, 1 H) 7.59 (d, J=8.8 Hz, 1 H) 8.05 (dd, J=8.8, 1.4 Hz, 1 H) 8.16 (d, J=9.2 Hz, 1 H) 8.31 (s, 1 H) ppm. MS (DCI/NH3) m/z 336 (M+H)*.Example 20C (R)-3-r6-(3-Methyl-1H-indazol-5-yl)-pyridazin-3-ylloxy]-1-aza-b{cvclo[2.2.2]octane fumarate The product of Example 20B (68 mg, 0.11 mmol) was treated with fumaric acid (Aldrich, 14 mg, 0.12 mmol) in EtOAc/MeOH (v.10:1, 5 ml) to provide the title compound as solid (59.1 mg, 65%). 1H NMR (MeOH-D4, 300 MHz) 1.82 - 2.18 (m, 3 H) 2.27 - 2.42 (m, 1 H) 2.55 - 2.66 (m, 4 H) 3.21 - 3.43 (m, 5 H) 3.82 - 3.95 (m, 1 H) 5.47 - 5.57 (m, 1 H) 6.68 (s, 2 H) 7.34 (d, J=9.2 Hz, 1 H) 7.60 (d, J=8.8 Hz, 1 H) 8.06 (dd, ,7=8.8,1.7 Hz, 1 H) 8.21 (d, J=9.2 Hz, 1 H) 8.32 (s, 1 H) ppm. MS (DCI/NH3) m/z 336(M+H)+. Anal. Calculated for Ci9H2iN50-1.0 C4H4O4-0.35 H20: C, 60.35; H, 5.66; N, 15.30. Found: C, 60.06; H, 5.40; N, 15.56. Example 21 (R)-3-[6-(1-Methyl-1H-indol-5-vn-pvridazin-3-yloxy}-1-aza-bicvclor2.2.21octane trifluoroacetate The product of Example 4A (120 mg, 0.5 mmol) was coupled with N-methyl-indole-5-boronic acid (Aldrich, 250 mg, 1.5 mmol) catalyzed by Pd2(dba)3 (24 mg, 0.025 mmol) and (lBu3P)2Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg, 1.5 mmol) in dioxane (8 ml) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.2% v. TFA) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (109.9 mg, 49%). 1H NMR (MeOH-D4, 300 MHz) 1.91 - 2.25 (m, 3 H), 2.34 - 2.48 (m, 1 H), 2.61 - 2.70 (m, 1 H), 3.33 - 3.56 (m, 5 H), 3.86 (s, 3 H), 3.94 -4.04 (m, 1 H), 5.50 - 5.59 (m, 1 H), 6.56 (d, J=3.1 Hz, 1 H), 7.25 (d, J=3.1 Hz, 1 H), 7.29 - 7.36 (m, 1 H), 7.52 (d, J=8.8 Hz, 1 H), 7.81 (dd, J=8.6,1.9 Hz, 1 H), 8.10 -8.19 (m, 2 H) ppm. MS (DCI/NH3) m/z 335 (M+H)+. Anal. Calculated for C20H22N4O-1.075 C2F3O2H: C, 58.22; H, 5.09; N, 12.26. Found: C, 58.21; H, 5.00; N, 12.30. Example 22 (R)-(5-[6-(-1-Aza-bicvclo[20.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-vlmethvl)- dimethvl-amine bisffumarate) Example 22A (R)-{5-[6-(1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl)-1H-indol-3-ylmethvl!- dimethyl-amine The product of Example 9B (150 mg, 0.47 mmol) was treated with HCHO (Aldrich, 37%, 76 mg, 0.94 mmol) and dimethylamine (Aldrich, 42 mg, 0.94 mmol) in dioxane/HOAc (v. 1:1, 5 ml) at ambient temperature for 16 hours. It was then concentrated and the title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HCO3, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (80 mg, 45%). 1H NMR (MeOH-D4, 300 MHz) 1.59 -1.75 (m, 1 H), 1.77 -1.99 (m, 2 H), 2.07 - 2.23 (m, 1 H), 2.36 - 2.44 (m, 1 H), 2.60 - 2.69 (m, 6 H), 2.91 - 3.13 (m, 5 H), 3.52 - 3.65 (m, 1 H), 4.22 (s, 2 H), 5.32 - 5.40 (m, 1 H), 7.30 (d, J=9.5 Hz, 1 H), 7.49 (s, 1 H), 7.56 (d, J=8.5 Hz, 1 H), 7.81 (dd, J=8.5,1.7 Hz, 1 H), 8.15 (d, J=9.5 Hz, 1 H), 8.29 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+. Example 22B (R)-{5-[6-(1-Aza-bicvclo[2.2.2]oct-3-yloxy)-pvridazin-3-yl]-1H-indol-3-vlmethyl}- dimethyll-amine bisffumarate) The product of Example 22A (80 mg, 0.21 mmol) was treated with fumaric acid (Aldrich, 49 mg, 0.42 mmol) in EtOAc / MeOH (v. 10:1) to give the title compound as white solid (74.8 mg, 53%). 1H NMR (MeOH-D4, 300 MHz) 1.79 - 2.17 (m, 3 H), 2.25 - 2.41 (m, 1 H), 2.54 - 2.61 (m, 1 H), 2.84 (s, 6 H), 3.19 - 3.42 (m, 5 H), 3.78 - 3.90 (m, 1 H), 4.50 (s, 2 H), 5.45 - 5.54 (m, 1 H), 6.66 (s, 5 H), 7.34 (d, J=9.2 Hz, 1 H), 7.54 - 7.63 (m, 2 H), 7.84 (dd, J=8.5,1.7 Hz, 1 H), 8.17 (d, J=9.2 Hz, 1 H), 8.35 (s, 1 H) ppm. MS (DCI/NH3) m/z 378(M+H)+. Anal. Calculated for C22H27N5O-2.5 C4H4O4-0.5 H20: C, 56.80; H, 5.66; N, 10.35. Found: C, 56.62; H, 5.78; N, 10.09. Example 23 ( R)-3-[6-(1 H-lndol-5-vn-pyridazin-3-yloxy]-1 -aza-bicvclo[2.2.2]octane 1 -oxidetrifluoroacetate The product of Example 9B was treated with H2O2 (Aldrich, aq. 30% 1 ml, 8.8 mmol) in acetonitrile (3 mL) for 5 h. The mixture was quenched by Na2SO3 solution carefully until no more peroxide was noticed, and it was then concentrated under vacuum. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (15.6 mg, 13%). 1H NMR (MeOH-d4, 300 MHz) 2.14 - 2.38 (m, 3 H) 2.55 - 2.71 (m, 2 H) 3.68 - 3.92 (m, 5 H) 4.37 - 4.47 (m, J=8.5 Hz, 1 H) 5.62 - 5.70 (m, J=4.4 Hz, 1 H) 6.57 (d, J=2.0 Hz, 1 H) 7.30 - 7.38 (m, 2 H) 7.52 (d, J=8.5 Hz, 1 H) 7.74 (dd, J=8.6, 1.8 Hz, 1 H) 8.13 - 8.20 (m, 2 H) ppm. MS (ESI) m/z 337(M+H)+. Anal. Calculated for C19H2oN4O2-1.15CF3CO2H: C, 54.72; H, 4.56; N, 11.98. Found: C, 54.72; H, 4.07; N, 12.08. Example 24 6-{6-[(3R)1-Aza-bicvclor2.2.21oct-3-yloxy]-pyridazin-3-yl)-benzothiazol-2-vlamine trifhvdroaen chloride) Example 24A 6-(4-Bromo-phenyl)-4.5-dihvdro-2H-pyridazin-3-one 4-(4-Bromo-phenyl)-4-oxo-butyric acid (Aldrich, 25.0 g, 97.3 mmol) was treated with NH2NH2-H2O (Aldrich, 55%, 9.1 mL, 156 mmol) in EtOH (Aldrich, 100 mL) at refluxing for 2h. It was cooled down to ambient temperature and the white solid was filtered off to give the title compound (24.2 g, 98%) 1H NMR (CDCI3,300 MHz) 5 2.50 - 2.76 (m, 2 H), 2.85 - 3.09 (m, 2 H), 7.43 - 7.71 (m, 4 H), 8.55 (s, 1 H) ppm. MS (DCI/NH3) m/z 253 (M+H)+, 255 (M+H)*, 270 (M+NH^, 272 (M+NH4)+. Example 24B 6-(4-BrQmo-Dhenvh-4.5-dihydro-2H-pvridazin-3-one The product of Example 24A (24.0 g, 95 mmol) was oxidized with bromine (Aldrich, 18.81g, 6.1 ml, 104.5 mmol) in HOAc (Aldrich, 200 mL) at 100°C for 1h. The brown mixture was then cooled down to ambient temperature. The white solid was filtered off and the filtrate was washed with water (2 x 20 ml). The solid was collected and dried under vacuum to give the title compound (25.0 g, 100%). 1H NMR (CDCI3, 300 MHz) 6 7.07 (d, J=10.2 Hz, 1 H), 7.55 - 7.69 (m, 4 H), 7.72 (d, J=9.8 Hz, 1 H) ppm. MS (DCI/NH3) m/z 251 (M+H)+, 253 (M+H)+, 268 (M+NH4)+, 270 (M+NH4)+. Example 24C 3-(4-Bromo-phenvn-6-chloro-pyridazine The product of Example 24B (25.0g, 100 mmol) was stirred in POCI3 (Aldrich, 200 ml) at 100°C for 18 h. Most of POCI3 was then distilled off (around 150 ml was collected). The residue was then poured into 300 ml of ice/water and stirred vigorously for 1 h. The solid was filtered off. The filtrate was washed with water (2 x 50 mL) and dried under vacuum to give the title compound (26.2 g, 98%). 1H NMR (MeOH-D4, 300 MHz) 6 7.72 (d, J=8.8 Hz, 2 H), 7.86 (d, J=8.8 Hz, 1 H), 8.02 (d, >8.8 Hz, 2 H), 8.19 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 269 (M+H)+, 271 (M+H)*, 273 (M+H)+. Example 24D (3R)-3-[6-(4-Bromo-phenyl)-pyridazin-3-yloxy]-1-aza-bicvclor2.2.21octane The product of Example 24C (2.43 g, 9 mmol) was coupled with the product of Example 4A (1.27g, 10 mmol) using f-BuOK (Aldrich, 1.12g, 10 mmol) as base in THF (anhydrous, Aldrich, 50 ml) according to the procedure of Example 7A. The title compound was purified by chromatography (SI02, CH2CI2: MeOH : NH3-H20, 90:10:2, Rf. 0.30) as slightly yellow solid (3.30g, 100%). 1H NMR (MeOH-D4, 300 MHz) 1.47 -1.66 (m, 1 H), 1.66 -1.93 (m, 2 H), 1.96 - 2.18 (m, 1 H), 2.23 - 2.42 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.38 - 3.58 (m, 1 H), 5.17 - 5.47 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.59 - 7.78 (m, 2 H), 7.82 - 7.99 (m, 2 H), 8.06 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 360 (M+H)+, 362 (M+H)+. Example 24E {4-[6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl]-phenyl)-benzhvdrylidene- amine The product of Example 24D (360 mg, 1 mmol) was coupled with benzhydrylideneamine (Aldrich, 270 mg, 1.5 mmol) under the catalysis of Pd2(dba)3 (Aldrich, 18.3 mg, 0.02 mmol) and Xantphos (Strem Chemicals, 36 mg, 0.06 mmol) with t-BuON,a (Aldrich, 150 mg, 1.5 mmol) in toluene (anhydrous, Aldrich, 10 ml) at 100°C for 2h. The mixture was then cooled down to ambient temperature and diluted with EtOAc (50 mL), washed with water (2x5 ml). The organic solution was concentrated and the title compound was purified by chromatography (SiO2, CHkCb : MeOH : NH3-H2O, 90:10:1, Rf. 0.4) as a solid (360 mg, yield, 78%). 1H NMR (300 MHz, CD3OD) 5 1.45-1.63 (m, 1 H), 1.64-1.94 (m, 2 H), 1.94-2.13 (m, 1 H), 2.23 - 2.41 (m, 1 H), 2.71 - 3.06 (m, 5 H), 3.39 - 3.55 (m, 1 H), 5.10 - 5.37 (m, 1 H), 6.82 -6.93 (m, 2 H), 7.12 - 7.23 (m, 3 H), 7.25 - 7.35 (m, 3 H), 7.39 - 7.57 (m, 3 H), 7.67 -7.74 (m, 2 H), 7.74 - 7.83 (m, 2 H), 7.96 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 461 Example 24F 446-f(3RV-1-Aza-bicvclor2.2.21oct-3-yloxy]-pyridazin-3-vl)-phenvlamine The product of Example 24E (360 mg, 0.78 mmol) was treated with HCI (aq. 10%, 5 ml) in THF (5 mL) at ambient temperature for 4 h. It was then concentrated and the title compound was purified by chromatography (Si02, CHaCb : MeOH : NH3-H20, 90:10:1, Rf. 0.1) as solid (210 mg, yield, 90%). 1H NMR (300 MHz, CD3OD) 6 1.44 - 1.66 (m, 1 H), 1.65 - 1.94 (m, 2 H), 1.95-2.16 (m, 1 H), 2.20 - 2.40 (m, 1 H), 2.68 - 3.06 (m, 5 H), 3.37 - 3.57 (m, 1 H), 5.15 - 5.37 (m, 1 H), 6.65 - 6.89 (m, 2 H), 7.18 (d, J=9.5 Hz, 1 H), 7.55 - 7.81 (m, 2 H), 7.93 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 297 (M+H)+. ' Example 24G 6-{6-[(3R)-1-Aza-bicvclor2.2.21oct-3-yloxy]-pvridazin-3-yl}-benzothiazol-2-vlamine The product of Example 24F (150 mg, 0.5 mmol) was treated with KSCN (Aldrich, 97 mg, 1 mmol) and bromine (Aldrich, 96 mg, 0.6 mmol) in HOAc (5 mL) at ambient temperature for 0.5 h. It was then quenched with Na2SO3(aq. 10%, 1 ml) and concentrated. The title compound was purified by chromatography (SiOa, CHaCfe : MeOH : NH3-H2O, 90:10:2, Rf. 0.1) as solid (170 mg, yield, 80%). 1H NMR (300 MHz, CD3OD) 6 1.60-1.70 (m, 1 H), 1.72 - 1.98 (m, 2 H), 2.02 - 2.19 (m, 1 H), 2.23 -2.42 (m, 1 H), 2.82 - 3.13 (m, 5 H), 3.42 - 3.68 (m, 1 H), 5.15 - 5.54 (m, 1 H), 7.26 (d, J=9.2 Hz, 1 H), 7.49 (d, J=8.5 Hz, 1 H), 7.87 (dd, J=8.Q, 1.9 Hz, 1 H), 8.07 (d, J=9.5 Hz, 1 H), 8.23 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 354 (M+H)*. Example 24H 6-{6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-Pvridazin-3-yl)-benzothiazol-2-vlamine trifhvdroaen chloride) The product of Example 24G (170 mg, 0.48 mmol) was treated with HCI (Aldrich, 4 M in dioxane, 0.5 ml, 2 mmol) in EtOAc (anhydrous, Aldrich, 5 ml) at ambient temperature for 0.5 h to give the title compound as a yellow solid (170 mg, yield, 77%). 1H NMR 8 1.88 - 2.29 (m, 3 H) 2.30-2.42 (m, 1 H) 2.57 - 2.75 (m, 1 H), 3.33 - 3.60 (m, 5 H), 3.99 (dd, J=14.2, 8.1 Hz, 1 H), 5.41 - 5.71 (m, 1 H), 7.50 (d, J=9.2 Hz, 1 H), 7.68 (d, J=8.8 Hz, 1 H), 8.16 (dd, J=8.5,1.7 Hz, 1 H), 8.26 (d, J=9.2 Hz, 1 H), 8.48 (d, J=1.4 Hz, 1 H) ppm; MS (DCI/NH3): 354 (M+H)+. Anal. Calculated for C18H19N5OS-3.00HCl.1.00H20: C, 44.96; H, 5.03; N, 14.56. Found: C, 44.70; H, 5.17; N, 14.24. Example 25 (3R)-3-[6-(3-Bromo-1H-indol-5-yl)-pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane trimvdroaen chloride) Example 25A (3R)-3-[6-(3-Bromo-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 9B (160 mg, 0.5 mmol) was dissolved in MeCN (10 mL) and treated with HOAc (Sigma, 60 mg, 1 mmol) for 10 min. N-bromosuccinimide (Aldrich, 110 mg, 0.6 mmol) in MeCN (Aldrich, 5 mL) was slowly added over 5 min. The mixture was stirred for 1 hour at ambient temperature and concentrated under vacuum. The title compound was purified by chromatography (Si02, CH2CI2: MeOH : NH3-H2O, 90:10:1, Rf. 0.15) as a solid (70 mg, yield, 35%). 1H NMR (300 MHz, CD3OD) 5 1.55-1.62 (m, 1 H), 1.70 -1.96 (m, 2 H), 2.05-2.20 (m, 1 H), 2.29 - 2.43 (m, 1 H), 2.74 - 3.13 (m, 5 H), 3.42 - 3.66 (m, 1 H, 5.24 - 5.46 (m, 1 H), 7.27 (d, J=9.2 Hz, 1 H), 7.38 (s, 1 H), 7.53 (d, -7=8.5 Hz, 1 H), 7.82 (dd, J=8.5,1.7 Hz, 1 H), 8.05 (s, 1 H), 8.11 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): 399 (M+H)+, 401 (M+H)+. Example 25B (3R)-3-[6-(3-Bromo-1H-indol-5-yl)-pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane trimvdroaen chloride) The product of Example 25A (50 mg, 0.125 mmol) was treated with HCI (Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 ml) at ambient temperature for 1h to provide the title compound as yellow solid (60 mg, yield, 95%). 1H NMR (300 MHz, CD3OD) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.56 (m, 1 H), 2.63 - 2.80 (m, 1 H), 3.35 - 3.71 (m, 5 H), 3.81 - 4.10 (m, 1 H), 5.37 - 5.74 (m, 1 H), 7.56 (s, 1 H), 7.72 (d, J=8.5 Hz, 1 H) 7.80 (dd, J=8.5, 1.8 Hz, 1 H), 8.01 (d, J=9.5 Hz, 1 H) 8.21 (d, J=1.4 Hz, 1 H), 8.76 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 399 (M+H)*, 401 (M+H)+. Anal. Calculated for Ci9H19BrN4O -3.00 HCM.50 H2O: C, 42.60; H, 4.70; N, 10.46. Found: C, 42.59; H, 4.79; N, 10.09. Example 26 5-{6-[(3R)- 1 -Aza-bicvclo[2.2.2]oct-3-vloxvl-Dvridazin-3-yl}-1 .3-dihvdro-indol-2-one bis(hydroaen chloride) Example 26A 5,(4.4.5.5-Tetramethvl-[1.3.2]dioxaboroian-2-yl)-1.3-dihvdro-indol-2-one 5-Bromo-1,3-dihydro-indol-2-one (Aldrich, 1.06 g, 5 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 1.52 g, 6 mmol) catalyzed by PdCI2(dppf)2-CH2CI2 (Aldrich, 82 mg, 0.1 mmol) using KOAc (Aldrich, 0.98 g, 10 mmol) as base in dioxane (anhydrous, Aldrich, 50 ml) at 80°C for 10h. After being cooled down to ambient temperature, the mixture was diluted with EtOAc (50 ml) and washed with brine (2 x 10 ml). The organic solution was then concentrated under vacuum. The 81 title compound was punned by chromatography (Si02, hexane : EtOAc, 70:30, Rf. 0.5) as a solid (0.96 g, yield, 74%). 1H NMR (300 MHz, CDCI3) 5 1.24 (s, 3 H), 1.28 (s, 3 H), 1.34 (s, 6 H), 3.69 (s, 2 H), 6.86 (d, J=7.8 Hz, 1 H), 7.57 - 7.78 (m, 2 H) ppm. MS (DCI/NHs): 260 (M+H)+. Example 26B 5-(6-[(3R)- 1 -Aza-bicvclo[2.2.2]oct-3-yloxy]-Pvridazin-3-yl}-1.3-dihvdro-indol-2-one The product of Example 4A (240 mg, 1 mmol) was coupled with the product of Example 26A (520 mg, 2 mmol) catalyzed by PdCI2(PPh3)2 (Aldrich, 35 mg, 0.05 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 52.5 mg, 0.15 mmol) in dioxane/EtOH/Na2GO3 (aq, 1 M) (v. 1/1/1,4.5 mL) at 130°C at 330 watts for 15 min in an Emry™ Creator microwave. The inorganic solid was filtered off with a syringe filter and the mixture was then directed purified by chromatography (SiO2, EtOAc: MeOH (v. 2% NH3.H2O), 50:50, Rf. 0.2) to give the title compound (240 mg, 71%). 1H NMR (300 MHz, MeOH-D4) 5 1.53 - 1.72 (m, 1 H), 1.73 -1.96 (m, 2 H), 2.05 - 2.22 (m, 1 H), 2.24 - 2.49 (m, 1 H), 2.83 - 3.15 (m, 5 H), 3.34 (S, 2 H), 3.47 -3.65 (m, 1 H), 5.16 - 5.49 (m, 1 H), 7.02 (d, J=7.7 Hz, 1 H), 7.25 (d, J=9.2 Hz, 1 H), 7.73 - 7.90 (m, 2 H), 8.01 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 337 (M+H)+. Example 26C • 5-(6-[(3R)-1 -Aza-bicvclo[2.2.2]oct-3-yloxy]-Dvridazin-3-yl}1.3-dihvdro-indol-2-one bisfhvdroaen chloride) The product of Example 26B (80 mg, 0.24 mmol) was treated with HCI (Aldrich, 4 M in dioxane, 0.25 mL, 1 mmol) in EtOAc (anhydrous, 5 mL) at ambient temperature for 1 h to provide the title compound as yellow solid (100 mg, yield, 100%). 1H NMR (300 MHz, MeOH-D4) 8 1.89 - 2.28 (m, 3 H), 2.29 - 2.49 (m, 1 H), 2.60-2.72 (m, 1 H), 3.34 - 3.63 (m, 5 H), 3.67 (s, 2 H), 3.81 - 4.10 (m, 1 H), 5.45 -5.71 (m, 1 H), 7.12 (d, J=6.1 Hz , 1 H), 7.77 (d, J=9.2 Hz, 1 H), 7.82 - 7.97 (m, 1 H), 8.46 (d, J=9.5 Hz, 1 H) ppm; MS (DCI/NH3): 337 (M+H)+. Anal. Calculated for C19H20N4O2-2.00 HCI-2.00 H20: C, 51.24; H, 5.88; N, 12.58. Found: C,51.34;H, 5.75; N, 12.62. 82 Example 27 5-{6-[(3R)-1 -Oxy-1 -Aza-bicvclo[2.2.2]oct-3-vloxv1-pyridazin-3-yl)-1.3-dihvdro-indol-2- one bisfhvdroaen chloride) Example 27A 5-(6-[( 3R)-1 -Oxv-1 -Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl)-1.3-dihvdro-indol-2- one The product of Example 26B (100 mg, 0.30 mmol) was treated with H2O2 (Aldrich, 30%, 0.5 ml, 1.3 mmol) in MeCN / H2O (v. 4 /1,10 ml) at 60°C for 70 hours according to the procedure of Example 23. The title compound was purified by chromatography (SiO2, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.1) as solid (80 mg, 76%). 1H NMR (300 MHz, MeOH-D4) 5 2.01 - 2.29 (m, 3 H), 2.37 - 2.61 (m, 2 H), 3.33 - 3.54 (m, 5 H), 3.68 (s, 2 H), 3.87 - 4.18 (m, 1 H), 5.46 - 5.77 (m, 1 H), 7.03 (d, J=8.1 Hz, 1 H), 7.31 (d, J=9.5 Hz, 1 H), 7.75 - 7.93 (m, 2 H), 8.06 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3): 353 (M+H)*. Example 27B 5-{6-[(3R)-1 -Oxy-1 -Aza-bicvclo[2.2.2]oct-3-yloxy]-Dvridazin-3-yl}1 ,3-dihvdro-indol-2- one bis[hydroaen chloride) The product of Example 27A (80 mg, 0.23 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.25 mL, 1 mmol) in /-PrOH (5 ml) at ambient temperature for 1h to provide the title compound as yellow solid (90 mg, yield, 93%). 1H NMR 8 2.10 - 2.50 (m, 3 H), 2.54 - 2.81 (m, 2 H), 3.35 (s, 2 H), 3.71 - 3.94 (m, 4 H), 4.02 (d, J=13.2 Hz, 1 H), 4.30 - 4.58 (m, 1 H), 5.51 - 5.86 (m, 1 H), 7.18 (d, J=8.9 Hz, 1 H), 7.84 - 8.00 (m, 2 H), 7.99 (d, J=9.2 Hz, 1 H), 8.63 (d, J=9.2 Hz, 1 H) ppm; MS (DCI/NH3): 353 (M+H)*. Anal. Calculated for Ci9H2oN4O3 -2.00 HCI-1.65 H20: C, 50.15; H, 5.60; N, 12.31. Found: C, 49.77; H, 5.29; N, 12.03. Example 28 5-{6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl}-1.3-dihvdro-benzoimidazol- 2-one trifluroacetate Example 28A (4-Bromo-2-nitro-phenyl)-carbamic acid tert-butvl ester 4-Bromo-2-nitro-phenylamine (Aldrich, 10.8 g, 50 mmol) was treated with di(tert-butyl) dicarbonate (Aldrich, 11.99 g, 55 mmol) in THF (Aldrich, 100 ml) at refluxing for 6 hours. It was then concentrated and the title compound was purified by recrystallization in EtOH as white solid (12.8 g, yield, 81%). 1H NMR (300 MHz, MeOH-D4) 6 1.40 (S, 9 H), 7.21 (d, J=8.5 Hz, 1 H), 7.76 (dd, J=8.4, 2.3 Hz, 1 H), 8.21 (d, J=2.1 Hz, 1 H) ppm. MS (DCI/NH3): 334 (M+H)+, 336 (M+H)+. Example 28B r2-Nitro-4-f4.4.5.5-tetramethvl-n .3.21dioxaborolan-2-yl)phenvn-carbamic acid tert-butvl ester The product of Example 28A (10.05 g, 30 mmol) was coupled with with bis(pinacolato)diboron (Aldrich, 9.14 g, 36 mmol) under the catalysis of PdCI2(dppf)2-CH2Cl2 (Aldrich, 490 mg, 0.6 mmol) with KOAc (Aldrich, 6.0 g, 60 mmol) in dioxane (anhydrous, Aldrich, 150 ml) at 80°C for 10 hours according to the procedure of Example 26A. The title compound was purified by chromatography (SiO2, hexane : EtOAc, 70:30, Rf. 0.5) as solid (9.0 g, yield, 83%). 1H NMR (300 MHz, CDCI3) 5 1.37 (s, 9 H), 1.38 (s, 12 H), 7.99 (d, J=1.4 Hz, 1 H), 8.02 (d, J=1.4 Hz, 1 H), 8.45 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3): 382 (M+NH4)*. Example 28C (4-{6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-Dvridazin-3-yl}-2-nitro-phenyl)-carbamic acid tert-butvl ester The product of Example 9A (240 mg, 1 mmol) was coupled with the product of Example 28B (0.72, 2 mmol) under the catalysis of Pd2(dba)3 (24 mg, 0.025 mmol) and ('BuaP^Pd (26 mg, 0.05 mmol) with CsF (Strem Chemicals, 228 mg, 1.5 mmol) in dioxane (8 ml) and DMF (Aldrich, 1 ml) at 80°C under N2 for 16 hours according to the procedure of Example 20B. The title compound was purified by chromatography (SiO2, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.3) as yellow solid (350 mg, 79%). 1H NMR (300 MHz, MeOH-D4) 6 1.40 (s, 9 H), 1.51 -1.70 (m, 1 H), 1.70 -1.98 (m, 2 H), 2.00 - 2.23 (m, 1 H), 2.37 - 2.51 (m, 1 H), 2.71 - 3.18 (m, 5 H), 3.47 - 3.69 (m, 1 H), 5.33 - 5.49 (m, 1 H), 7.30 (d, J=9.2 Hz, 1 H), 7.54 (d, J=8.5 Hz, 1 H), 7.62 (s, 1 H), 8.14 (d, J=9.5 Hz, 1 H), 8.37 (dd, ^=8.1, 2.0 Hz, 1 H), 8.80 (d, J=2.0 Hz, 1 H) ppm. MS (DCI/NH3): 442 (M+H)+. Example 28D 4-{6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-Pvridazin-3-yl)-2-nitro-phenvlamine The product of Example 28C (350 mg, 0.79 mmol) was treated with HCI (Aldrich, 4 M in dioxane, 2 ml, 8 mmol) in EtOH (5 ml) at ambient temperature for 1 h. The mixture was concentrated and the title compound was purified by chromatography (SiO2, EtOAc: MeOH (v. 2% NH3.H2O), 50:50, Rf. 0.1) as white solid (250 mg, 93%). 1H NMR (300 MHz, MeOH-D4) 5 1.54 -1.66 (m, 1 H), 1.72 -2.02 (m, 2 H), 2.07 - 2.24 (m, 1 H), 2.35 - 2.57 (m, 1 H), 2.79 - 3.18 (m, 5 H), 3.48 -3.69 (m, 1 H), 5.27 - 5.47 (m, 1 H), 7.10 (d, J=8.8 Hz, 1 H), 7.22 (d, J=9.5 Hz, 1 H), 7.66 (s, 1 H), 7.98 (d, J=9.2 Hz, 1 H), 8.08 (dd, J=9.0, 2.2 Hz, 1 H), 8.68 (d, J-2A Hz, 1 H) ppm. MS (DCI/NH3): 342 (M+H)+. Example 28E 4-(6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl}-benzene-1.2-diamine The product of Example 28D (200 mg, 0.59 mmol) was hydrogenated under the catalysis of Pd/C (Aldrich, 10wt.%, 50 mg) in EtOH (10 ml) under hydrogen at ambient temperature for 10 h. After the reaction went to completion, the catalyst was removed through a short column of diatomaceous earth (~ 2 g) and the filtrate was washed with EtOH (2x5 ml). The ethanol solution was concentrated to give the title compound (180 mg, yield, 98%). 1H NMR (500 MHz, CD3-OD) 8 1.58 - 1.73 (m, 1 H), 1.76 - 2.00 (m, 2 H), 2.06 - 2.27 (m, 1 H), 2.29 - 2.47 (m, 1 H), 2.81 - 3.20 (m, 5 H), 3.52 - 3.68 (m, 1 H), 5.11 - 5.57 (m, 1 H), 6.78 (d, J=8.2 Hz, 1 H), 7.12 - 7.26 (m, 2 H), 7.32 (d, J=2.1 Hz, 1 H), 7.92 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3): 312 (M+H)+. Example 28F 5-{6-[3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl}-1.3-dihvdro-benzoimidazol- 2-one trifluroacetate The product of Example 28E (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 ml) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.2% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 22%). 1H NMR (500 MHz, CD3-OD) 5 1.94 - 2.33 (m, 3 H), 2.30 - 2.48 (m, 1 H), 2.65 - 2.79 (m, 1 H), 3.38 - 3.70 (m, 6 H), 3.94 - 4.06 (m, 1 H), 5.41 - 5.73 (m, 1 H), 7.31 (d, J=7.6 Hz, 1 H), 7.62 - 7.78 (m, 2 H), 8.00 (d, J=7.0 Hz, 1 H), 8.65 (d, J=7.3 Hz, 1 H) ppm; MS (DCI/NH3): 338 (M+H)+. Anal. Calculated for C18H19N5O2 -1.15 CF3C02H -2.30 H2O: C, 47.81; H, 4.89; N, 13.73. Found: C, 47.69; H, 5.27; N, 14.09. Example 29 (R)-3-[6-(1H-Benzoimidazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicvclor2.2.21octane Example 29A (R)-N-{4-[6-(1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl]-phenyl}-acetamide The product of Example 9A (182 mg, 0.76 mmol), N-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (Aldrich, 500 mg, 1.9 mmol), dichlorobis(triphenylphosphine)palladium (II) (Aldrich, 53 mg, 0.076 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 6.5 mg, 0.019 mmol) were combined with 1 mL each of ethanol, p-dioxane, and 1 M aq. sodium carbonate. The mixture was heated in a sealed tube to 150 °C at 330 watts for 10 min in an Emry™ Creator microwave. The mixture was cooled to room temperature, filtered through Celite®, and concentrated onto silica. The product was purified by column chromatography (SiO2, 5% methanol containing 1% NH4OH -CH2CI2) to provide the title compound (203 mg, 79%).1H NMR (300 MHz, CD3OD) 8 1.96 (m, 1 H), 2.09 (m, 1 H), 2.16 (m, 1 H), 2.16 (s, 3 H), 2.38 (m, 1 H), 2.64 (td, J=6.5, 3.6 Hz, 1 H), 3.33 -3.53 (m, 6 H), 3.97 (dd, J=13.9, 8.1 Hz, 1 H), 5.54 (m, 1 H), 7.32 (d, J=9.4 Hz, 1 H), 7.69 - 7.78 (m, 2 H), 7.91 - 7.98 (m, 2 H), 8.11 (d, J=9.3 Hz, 1 H) ppm; MS (DCI/NH3): m/z 339 (M+H)+. Example 29B 4-{6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-yloxy]-pvridazin-3-yl}-2-nitro-phenvlamine trifiuoroacetate To an ice-cold solution of Example 29A (160 mg, 0.47 mmol) in cone, sulfuric acid (5 ml) was added 90% nitric acid (0.020 ml, 0.47 mmol). After 2 h at 4°C, the mixture was poured over ice and neutralized with ice-cold NaOH (1 N aq.). The mixture was concentrated and the residue was dissolved in MeOH and filtered to give a crude red solid. The product was purified by preparative RP HPLC (Symmetry® C-8, 7 µm, 40 x 100 mm; 10-90% MeCN / H20 with 0.2% v. TFA) to give the title compound (54 mg, 0.11 mmol, 23%). 1H NMR (400 MHz, CD3OD) 6 1.97 (m, 1 H), 2.03 - 2.23 (m, 2 H), 2.39 (m, 1 H), 2.65 (td, J=6.5, 3.6 Hz, 1 H), 3.35 -3.47 (m, 4 H), 3.49 (m, 1 H), 3.85 (m, 1 H), 3.97 (dd, J=14.0, 8.4 Hz, 1 H), 5.54 (m, 1 H), 7.12 (d, J=8.9 Hz, 1 H), 7.33 (d, J=9.2 Hz, 1 H), 8.04 (dd, J=8.9, 2.1 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.71 (d, J=2.1 Hz, 1 H) ppm. MS (ESI): m/z342 (M+H)+. Example 29C (R)-3-[6-(1H-Benzoimidazol-5-yl)-Pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 29B (29 mg, 0.064 mmol) was dissolved in 2.0 ml of methanol and 6 mg of Pd(OH)2/C (Aldrich, 10 wt%) was added. The mixture was stirred under 50 psi of H2 for 30 min. The solution was filtered through a nylon membrane and concentrated. The residue was dissolved in DMF (0.25 ml) and treated with excess triethylorthoformate (0.1 mL). The solution was heated at 80 °C for 2 h, then cooled down to ambient temperature and stirred for 4 h. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 µrn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 70/30 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (13 mg, 0.04 mmol, 63%). 1H NMR (300 MHz, CD3OD) 8 1.57 (m, 1 H), 1.73 -1.94 (m, 2 H), 2.08 (m, 1 H), 2.34 (td, J=6.4, 3.6 Hz, 1 H), 2.80 - 3.03 (m, 6 H), 3.50 (ddd, J=14.5, 8.1,1.5 Hz, 1 H), 5.32 (m, 1 H), 7.28 (d, J=9.2 Hz, 1 H), 7.74 (d, J=8.5 Hz, 1 H), 7.91 (d, J=8.5 Hz, 1 H), 8.11 (d, J=9.2 Hz, 1 H), 8.22 (s, 1 H), 8.25 (s, 1 H) ppm; MS (DCI/NH3): m/z 322 (M+H)*. Example 30 (S)-3-[6-(1H-lndol-5-yl)-Pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane fumarate Example 30A (S)-3-(6-Chloro-pvridazin-3-yloxy)-1-aza-bicvclo[2.2.2]octane The product of Example 13D (254 mg, 2 mmol) was coupled with 3,6-dichloropyridazine (Aldrich, 596 mg, 4 mmol) according to the procedure of Example 7A. The title compound was purified by flash chromatography (SiO2, CH2Cl2: MeOH : NH3-H2O, 90:10:2, Rf. 0.30) as solid (346 mg, 72%). 1H NMR (300 MHz, MeOH-D4) 5 1.47 -1.63 (m, J=12.9 Hz, 1 H), 1.65 -1.92 (m, 2 H), 1.94 - 2.10 (m, J=5.9, 3.6 Hz, 1 H), 2.22 - 2.32 (m, J=2.7 Hz, 1 H), 2.72 - 3.02 (m, 5 H), 3.36 - 3.49 (m, 1 H), 5.17 -5.28 (m, 1 H), 7.23 (d, J=9.2 Hz, 1 H), 7.65 (d, J=9.5 Hz, 1 H) ppm. MS (DCI/NH3) m/z 240 (M+H)+, 242 (M+H)+. Example 3OB (S)-3-[6-(1H-lndol-5-yl)-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 30A (270 mg, 1.1 mmol) was coupled with 5-indolylboronic acid (215 mg, 1.4 mmol) according to the procedure of Example 20B. The title compound was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 Mm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HC03, 0.1 M, PH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (200 mg, 57%). 1H NMR (300 MHz, MeOH-D4) 5 1.49 -1.63 (m, 1 H), 1.67 -1.92 (m, 2 H), 1.99 - 2.14 (m, 1 H), 2.28 - 2.36 (m, 1 H), 2.76 - 3.04 (m, 5 H), 3.48 (ddd, J=14.7, 8.2, 1.9 Hz, 1 H), 5.24 - 5.34 (m, 1 H), 6.56 (d, J=4.1 Hz, 1 H), 7.24 (d, J=9.5 Hz, 1 H), 7.30 (d, J=3.4 Hz, 1 H), 7.50 (d, J=8.5 Hz, 1 H), 7.73 (dd, J=8.6,1.9 Hz, 1 H) ,8.07 (d, J=9.5 Hz, 1 H), 8.13 (s, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Example 30C (S )-3-[6-(1 H-lndol-5-yl)-pvridazin-3-yloxy]-1 -aza-bicvclo[2.2.2]octane fumarate The product of Example 3OB (200 mg, 0.625 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH (v.10:1,10 mL) at ambient temperature for 10 hours to give title compound (240.2 mg, 85%). 1H NMR (300 MHz, MeOH-D4) 5 1.87 - 2.22 (m, 3 H), 2.31 - 2.45 (m, 1 H), 2.60 - 2.67 (m, 1 H), 3.30 - 3.50 (m, 5 H), 3.89 - 4.00 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.57 (d, J=3.1 Hz, 1 H), 6.68 (s, 2 H), 7.28 - 7.35 (m, 2 H), 7.52 (d, J=8.5 Hz, 1 H), 7.74 (dd, J=8.6,1.9 Hz, 1 H), 8.11 - 8.19 (m, J=9.5 Hz, 2 H) ppm. MS (DCI/NH3) m/z 321 (M+H)+. Anal. Calculated for C19H2oN40-1.0 C4O4H4-0.50 H2O: C, 62.01; H, 5.66; N, 12.58. Found: C, 61.79; H, 5.46; N, 12.43. Example 31 ( R)-3-[5-( 1 H-lndol-5-yl)-pvridin-2-yloxy]-1 -aza-bicvclo[2.2.2]octane trifluoroacetate Example 31A (R)-3-(5-Bromo-pyridin-2-yloxy)-1-aza-bicvclo[2.2.2]octane The product of Example 4A (1.27 g, 10 mmol) was coupled with 5-bromo-2-chloro-pyridine (Aldrich, 1.54 g, 8 mmol) according to the procedure of Example 7A. The title compound was purified by column chromatography (Si02, CHaCb: MeOH : NH3-H20, 90:10:1, Rf. 0.2) as a solid (2.0 g, yield, 88%). 1H NMR (MeOH-d4, 300 MHz) 1.49-1.64 (m, 1 H), 1.66-1.91 (m, 2 H), 1.97-2.11 (m, 1 H), 2.17-2.26 (m, 1 H), 2.77 - 3.05 (m, 5 H), 3.36 - 3.47 (m, 1 H), 5.02 - 5.10 (m, 1 H), 6.77 (d, J=8.8 Hz, 1 H), 7.78 (dd, J=8.8, 2.7 Hz, 1 H), 8.16 (t, J^2.5 Hz, 1 H) ppm. MS (DCI/NH3) m/z 283 (M+H)+, 285(M+H)+. Example 31B ( R)3-[5-(1 H-lndol-5-yl)-pyridin-2-yloxy]-1 -aza-bicvclo[2.2.2]octane trifluoroacetate The product of Example 31A (140 mg, 0.5 mmol) was coupled with 5-indolylboronic acid (Ryscor Science, 161 mg, 1.0 mmol) according to the procedure of Example 29A. The title compound was preparative HPLC (Xterra™, column, Xterra RP-18, 5 pm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.2% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (72.9 mg, 32%). 1H NMR (MeOH-d4, 300 MHz) 1.86 - 2.22 (m, 3 H), 2.31 - 2.46 (m, 1 H), 2.52 - 2.63 (m, 1 H), 3.29 - 3.50 (m, 5 H), 3.85 - 3.97 (m, 1 H), 5.34 - 5.42 (m, 1 H), 6.49 (d, J=2.4 Hz, 1 H), 6.93 (d, J=8.5 Hz, 1 H), 7.24 - 7.35 (m, 2 H), 7.46 (d, J=8.5 Hz, 1 H), 7.74 (d, J=1.7 Hz, 1 H), 8.00 (dd, J=8.6, 2.5 Hz, 1 H), 8.38 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3) m/z 320(M+H)+. Anal. Calculated for C20H21N3O1.14 CF3CO2H: C, 59.55; H, 4.97; N, 9.35. Found: C, 59.59; H, 4.99; N, 9.03. Example 32 (3R)-3-[5-( 1 H-lndol-4-yl)-Pvrimidin-2-yloxy]-1 -aza-bicvclo[2.2.2]octane 1 -oxide The product of Example 12A (10 mg, 0.03 mol) was oxidized with H202 (Aldrich, aq., 30%) according to the procedure of Example 23. The title compound was purified by chromatography [Si02, CH2CI2: MeOH (v. 5% NH3.H2O), 90 :10]. 1H NMR (300 MHz, CD3OD) 8 2.01 - 2.32 (m, 3 H), 2.42 - 2.64 (m, 2 H), 3.41 - 3.70 (m, 5H), 3.91 - 4.24 (m, 1 H), 5.39 - 5.59 (m, 1 H), 6.55 (d, J=4.0 Hz, 1 H), 7.12 (d, J=8.0 Hz, 1 H), 7.23 (t, J=8.0 Hz, 1 H), 7.36 (d, J=3.0 Hz, 1 H), 7.47 (d, J=8.0 Hz, 1 H), 8.96 (s, 2 H) ppm. Example 33 (3R)-3-(5-Benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicvclo[2.2.2]octane bls(hvdroaen chloride) Example 33A 1-Benzvloxy-4-bromo-2-nitro-benzene 4-Bromo-2-nitro-phenol (Aldrich, 2.18 g, 10 mmol) was treated with K2CO3 (Aldrich, 2.76 g, 20 mmol) in DMF (Aldrich, 100 mL) at ambient temperature for 20 min. Benzyl chloride (Aldrich, 1.52 g, 12 mmol) was added. The mixture was stirred at 100°C for 6 h. It was then poured into ice/water (200 ml) and stirred at ambient temperature for 10 hours. The white solid was filtered and dried to give the title compound (3.0 g, yield, 100%). 1H NMR (300 MHz, CDCI3) 5 5.23 (s, 2 H), 7.01 (d, J=9.2 Hz, 1 H), 7.31 - 7.49 (m, 5 H), 7.58 (dd, J=9.0,2.5 Hz, 1 H), 7.98 (d, J=2.7 Hz, 1 H) ppm. MS (DCI/NH3): 325 (M+H)+, 327 (M+H)+. Example 33B r2-Nitro-4-(4.4.5.5-tetramethvl-[1,3.21dioxaborolan-2-vl)-phenyl]-carbamic acid tert- butvl ester The product of Example 33A (3.0 g, 10 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 3.04 g, 12 mmol) according to the procedure of Example 28B. The title compound was purified by chromatography (SiO2, hexane : EtOAc, 70:30, Rf. 0.5) as a solid (3.05 g, yield, 86%). 1H NMR (300 MHz, MEOH-D4) 5 1.34 (s, 12 H), 5.30 (s, 2 H), 7.27 - 7.43 (m, 4 H), 7.42 - 7.51 (m, 2 H), 7.89 (dd, J=8.3,1.5 Hz, 1 H), 8.09 (d, J=1.7 Hz, 1 H) ppm. MS (DCI/NH3): 373 (M+NH4)*. Example 33C (3R)-3-[5-(4-Benzvloxy-3-nitro-phenyl]-pvrimidin-2-yloxy1-1-aza-bicvclo[2.2.2]octane The product of Example 11A (1.42 g, 5 mmol) was coupled with the product of Example 33B (2.50 g, 7.0 mmol) according to the procedure of Example 20B. The title compound was purified by chromatography (Si02, EtOAc: MeOH (v. 2% NH3.H20), 50:50, Rf. 0.3) as solid (1.75 g, 81%). 1H NMR (300 MHz, MeOH-D4) 5 1.46 - 1.61 (m, 1 H), 1.63 -1.92 (m, 2 H), 1.97 - 2.15 (m, 1 H), 2.17 - 2.33 (m, 1 H), 2.69 - 3.04 (m, 5 H), 3.35 - 3.49 (m, 1 H), 5.11 - 5.22 (m, 1 H), 5.34 (s, 2 H), 7.25 -7.55 (m, 5 H), 7.85 (dd, J=8.8,2.4 Hz, 1 H), 8.13 (d, J=2.0 Hz, 1 H), 8.63 (s, 1 H), 8.82 (s, 2 H) ppm. MS (DCI/NH3): 433 (M+H)+. Example 33D 2-Amino-4-{2-[(3R)-1-aza-bicvclo[2.2.2]oct-3-vloxv1-pvrimidin-5-yl}-phenol The product of Example 33C (380 mg, 0.88) was hydrogenated under the catalysis of Pd/C (Aldrich, 10 wt. %, 100 mg) according to the procedure of Example 28E. The title compound was obtained as yellow solid (220 mg, yield, 92%). 1H NMR (300 MHz, CD3OD) 8 1.47 -1.93 (m, 3 H), 1.95 - 2.35 (m, 2 H) 2.70 - 3.05 (m, 5 H), 3,33 - 3.48 (m, 1 H), 5.04 - 5.30 (m, J=8.8 Hz, 1 H), 6.72 - 6.88 (m, 2 H), 6.98 (d, J=1.7 Hz, 1 H), 8.70 (s, 2 H)ppm. MS (DCI/NH3): 313 (M+H)*. Example 33E (3R)-3-(5-Benzooxazol-5-vl-Dvrimidin-2-yloxy)-1-aza-bicvclo[2.2.21octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoformate (Aldrich, 0.5 ml) in DMF (1 ml) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 µm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HCO3, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (50.0 mg, 78%). 1H NMR (300 MHz, CD3-OD) 8 1.46 -1.64 (m, 1 H), 1.64 -1.93 (m, 2 H), 2.00 - 2.19 (m, 1 H), 2.19 - 2.39 (m, 1 H), 2.67 - 3.13 (m, 5 H), 3.36 - 3.51 (m, 1 H), 5.09 - 5.38 (m, 1 H), 7.72 (dd, J=8.5, 2.0 Hz, 1 H), 7.81 (d, J=8.9 Hz, 1 H), 8.03 (d, J=1.7 Hz, 1 H), 8.53 (s, 1 H), 8.87 (s, 2 H) ppm; MS (DCI/NH3): 323 (M+H)+. Example 33F (3R)-3-(5-Benzooxazol-5-yl-pvrimidin-2-yloxy)-1-aza-bicvclo[2.2.2]octane bisfhvdroaen chloride) The product of Example 33E (50 mg, 0.15 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.50 ml, 2.0 mmol) in EtOAc (5 ml) at ambient temperature for 1 hour to afford the title compound as yellow solid (55.0 mg, 93%). 1H NMR (300 MHz, CD3-OD) 5 1.83 - 2.28 (m, 3 H), 2.30 - 2.50 (m, 1 H), 2.58 - 2.75 (m, 1 H), 3.34 - 3.51 (m, 5 H), 3.84 - 3.97 (m, 1 H), 5.33 - 5.52 (m, 1 H), 7.15 (d, J=8.5 Hz, 1 H), 7.51 - 7.67 (m, 1 H), 7.80 (s, 1 H), 8.09 (s, 1 H), 8.81 (s, 2 H) ppm; MS (DCI/NH3): 323 (M+H)+. Anal. Calculated for C18H18N4O2-2.38 HCI -2.60 H2O: C, 47.41; H, 5.65; N, 12.29. Found: C, 47.33; H, 5.25; N, 11.92. Example 34 (3R)-3-[5-(2-Methyl-benzooxazol-5-yl]-pyrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane hvdroaen chloride Example 34A (3R)-3-r5-(2-Methyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthoacetate (Aldrich, 0.5 ml) in DMF (1 ml) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 µm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HCO3, 0.1 M, pH=10) (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%). 1H NMR (500 MHz, CD3OD) 5 1.51 -1.64 (m, 1 H), 1.66 -1.77 (m, 1 H), 1.78 -1.91 (m, 1 H), 2.02 - 2.16 (m, 1 H), 2.19 - 2.36 (m, 1 H), 2.67 (s, 3 H), 2.74 - 3.07 (m, 5 H), 3.37 - 3.48 (m, 1 H), 5.07 - 5.39 (m, 1 H), 7.62 (dd, J=8.5,1.3 Hz, 1 H), 7.68 (d, J=8.3 Hz, 1 H),7.87 (d, J=1.2 Hz, 1 H), 8.79 - 8.93 (s, 2 H) ppm; MS (DCI/NH3): 327 (M+H)+. Example 34B (3R)-3-[5-(2-Methyl-benzooxazol-5-yl)-pvrimidin-2-yloxy]-1-aza-bicvclor2.2.21octane hydrogen chloride The product of Example 34A (20 mg, 0.06 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.25 ml, 1.0 mmol) in EtOAc (3 ml) at ambient temperature for 1 hour to afford the title compound as yellow solid (20.0 mg, 92%). 1H NMR (500 MHz, CD3OD) 8 1.92 - 2.25 (m, 3 H), 2.33 - 2.47 (m, 1 H), 2.59 - 2.65 (m, 1 H), 2.65 - 2.71 (s, 3 H), 3.33 - 3.54 (m, 5 H), 3.87 - 4.00 (m, 1 H), 5.34 - 5.54 (m, 1 H), 7.63 (d, J= 8.5 Hz, 1 H), 7.70 (d, J= 8.5 Hz, 1 H), 7.88 (s, 1 H), 8.90 (s, 2 H) ppm; MS (DCI/NH3): 327 (M+H)*. Anal. Calculated for Ci8H»N402 -1.20 HCI -1.50 H2O: C, 56.39; H, 5.60; N, 13.45. Found: C, 56.05; H, 5.99; N, 13.76. Example 35 (3R)-3-[5-(2-Ethvl-benzooxazol-5-yl-Dvrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane bisfhvdroaen chloride) Example 35A (3R)-3-[5-(2-Ethvl-benzooxazol-5-yl)-pvrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthopropionate (Aldrich, 0.5 mL) in DMF (1 mL) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 µm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HCO3, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (20.0 mg, 30%). 1H NMR (500 MHz, CD3OD) 8 1.45 (t, J=7.6 Hz, 3 H), 1.49 -1.64 (m, 1 H), 1.66 -1.78 (m, 1 H), 1.79 -1.94 (m, 1 H), 2.04 - 2.16 (m, 1 H), 2.21 - 2.36 (m, 1 H), 2.72 - 3.11 (m, 7 H), 3.37 - 3.53 (m, 1 H), 5.07 - 5.31 (m, 1 H), 7.62 (dd, J= 8.5,1.7 Hz, 1 H) 7.69 (d, J= 8.6 Hz, 1 H), 7.89 (d, J=1.2 Hz, 1 H), 8.82 - 8.90 (m, 2 H) ppm; MS (DCI/NH3): 351 (M+H)*. Example 35B (3R)-3-[5-(2-Methvl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane bisfhvdroaen chloride) The product of Example 35A (20 mg, 0.06 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.25 ml, 1.0 mmol) in EtOAc (3 ml) at ambient temperature for 1 hour to afford the title compound as yellow solid (15.0 mg, 92%). 1H NMR (500 MHz, CD3-OD) 8 1.46 (t, J=7.6 Hz, 3 H), 1.89 - 2.25 (m, 3 H), 2.28 - 2.52 (m, 1 H), 2.54 - 2.72 (m, 1 H), 3.02 (q, J=7.6 Hz, 2 H), 3.22 - 3.56 (m, 5 H), 3.92 (dd, J=13.6, 8.7 Hz, 1 H), 4.99 - 5.63 (m, 1 H), 7.63 (d, J=8.5 Hz, 1 H), 7.71 (d, J=8.5 Hz, 1 H), 7.90 (s, 1 H), 8.90 (s, 2 H) ppm; MS (DCI/NH3): 351 (M+H)*. Anal. Calculated for C2oH22N402-2.00 HCI: C, 56.74; H, 5.71; N, 13.23. Found: C, 56.82; H, 5.69; N, 13.13. Example 36 (3R)-3-[5-(2-Phenvl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane bisfhvdroaen chloride) Example 36A (3R)-3-[5-(2-Phenvl-benzooxazol-5yl)-pyrimidin-2-yloxy]-1-aza-bicvclo[2.2.2]octane The product of Example 33D (62 mg, 0.2 mmol) was treated with triethyl orthobenzoate (Aldrich, 0.5 ml) in DMF (1 ml) at 100°C for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 Mm, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HCO3, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (40.0 mg, 50%). 1H NMR (500 MHz, CD3OD) S 1.52 -1.64 (m, 1 H), 1.68 -1.80 (m, 1 H), 1.80 -1.92 (m, 1 H), 2.06-2.18 (m, 1 H), 2.25-2.31 (m, 1 H), 2.75-3.10 (m, 5 H), 3.39 - 3.49 (m, 1 H), 5.14 - 5.27 (m, 1 H), 7.55 - 7.66 (m, 3 H), 7.69 (dd, J=8.5, 1.8 Hz, 1 H), 7.81 (d, J=8.2 Hz, 1 H), 8.00 (d, J=1.5 Hz, 1 H), 8.27 (dd, J=8.1,1.7 Hz, 2 H), 8.89 (s, 2H) ppm; MS (DCI/NH3): 399 (M+H)+. Example 36B (3R)-3-[5-(2-Phenvl-benzooxazol-5-yl)-Pvrimidin-2-yloxyl]-1-aza-bicvclo[2.2.2]octane bismydroaen chloride) The product of Example 36A (40 mg, 0.10 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.25 mL, 1.0 mmol) in EtOAc (3 ml) at ambient temperature for.1 hour to afford the title compound as yellow solid (20.0 mg, 92%). 1H NMR (500 MHz, CD3OD) 8 1.93 - 2.23 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.60 - 2.71 (m, 1 H), 3.34 -3.57 (m, 5 H), 3.90 - 3.99 (m, 1 H), 5.35 - 5.61 (m, 1 H), 7.54 - 7.68 (m, 3 H), 7.72 (dd, J=8.4,1.7 Hz, 1 H), 7.84 (d, J-8.5 Hz, 1 H), 8.03 (d, J=1.2 Hz, 1 H), 8.21 - 8.37 (m, 2 H), 8.98 (s, 2 H) ppm; MS (DCI/NH3): 399 (M+H)*. Anal. Calculated for C24H22N4O2-1.40HCI-1.50H20: C, 60.49; H, 5.58. Found: C, 60.12; H, 5.72. Example 37 (R)-5-[2-(1-Aza-bicvcio[2.2.2]oct-3-vloxv)-pvrimidin-5-yl]-3H-benzooxazol-2-one bis(hvdrochloride') Example 37A (R)-5-[2-(1-Aza-bicvclo[2.2.2]oct-3-yloxy)-pvrimidin-5-yl]-3H-benzooxazol-2-one The product of Example 33D (62 mg, 0.2 mmol) was treated with 1,1'-carbonyldiimidazole (Aldrich, 50 mg, 0.31 mmol) in THF/DMF (v. 1:1, 5 mL) at ambient temperature for 10h. It was then concentrated. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HCO3, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (60.0 mg, 34%). 1H NMR (500 MHz, CDs-OD) 5 1.46 -1.96 (m, 3 H), 2.02 - 2.18 (m, 1 H), 2.19 - 2.38 (m, 1 H), 2.70 - 3.11 (m, 5 H), 3.37 - 3.51 (m, 1 H), 5.08 - 5.29 (m, 1 H), 7.14 - 7.60 (m, 3 H), 8.79 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)*. Example 37B (R)-5-[2-(1-Aza-bicvclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2-one bisfhvdrochloride) I he product of Example 37A (60 mg, 0.18 mmol) was treated with HCI (Aldrich, 4M in dioxane, 0.25 ml, 1.0 mmol) in EtOAc (3 ml) at ambient temperature for 1 hour to afford the title compound as yellow solid (60.0 mg, 83%). 1H NMR (500 MHz, CD3OD) 5 1.89 - 2.28 (m, 3 H), 2.30 - 2.54 (m, 1 H), 2.61 - 2.76 (m, 1 H), 3.36 -3.52 (m, 5 H), 3.82 - 3.99 (m, 1 H), 5.40-5.52 (m, 1 H) 7.20 - 7.47 (m, 2 H), 7.68 (s, 1 H), 8.80 (s, 2 H) ppm; MS (DCI/NH3): 338 (M+H)+. Anal. Calculated for Ci8H18N4O3 •2.00HCI-1.50H20: C, 49.33; H, 5.29; N, 12.78. Found: C, 49.40; H, 5.07; N, 12.60. Example 38 (R)-3-[6-(1-Aza-bicvclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-9H-carbazole Example 38A 3-(4.4.5.5-Tetramethyl-[1.3.2]dioxaborolan-2-yl)-9H-carbazole 3-Bromo-9/-/-carbazole (Aldrich, 0.97 g, 3.96 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 1.13 g, 4.46 mmol) under the catalysis of dichloro [1,1I-bis(diphenylphosphino)ferrocene]palladium (II) dichloromethane (Aldrich, 103 mg, 0.125 mmol) with KOAc (Aldrich, 1.21 g, 12.3 mmol) in DMF (anhydrous, Aldrich, 25 ml) at 80°C overnight according to the procedure of Example 26A, The title compound was purified by chromatography (SiO2, gradient 5 to 50% EtOAc-hexanes) to give 0.80 g (2.73 mmol, 69% yield). 1H NMR (300 MHz, CDCI3) δ 1.40 (s, 12 H), 7.26 (s, 1 H), 7.40 - 7.47 (m, 3 H), 7.88 (d, J=7.0 Hz, 1 H), 8.11 (d, J=7.0 Hz, 2 H), 8.58 (s, 1 H) ppm. MS (DCI/NH3) m/z 294 (M+H)+. Example 38B (R)-3-[6-(1-Aza-bicvclo[2.2.2]oct-3-yloxy)-pvridazin-3-yl]-9H-carbazole The product of Example 9A (0.173g, 0.72 mmol) was coupled with the product of Example 38A (0.267 g, 0.91 mmol) under the catalysis of dichlorobis(triphenyl-phosphine)palladium(ll) (Aldrich, 5.3 mg, 0.007 mmol) and 2-(dicyclohexylphosphino)biphenyl (Strem Chemicals, 7.3 mg, 0.021 mmol) at 150 °C for 10 min. according to the procedure of Example 29A. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18 5 µm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (NH4HC03, 0.1 M, pH=10) (v. 40/60 to 70/30 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid. 1H NMR (300 MHz, CD3OD) 8 1.45 - 1.62 (m, 1 H), 1.68 -1.92 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.27 - 2.40 (m, Hz, 1 H), 2.75 - 3.05 (m, 5 H), 3.43 - 3.59 (m, Hz, 1 H), 5.22 - 5.42 (m, Hz, 1 H), 7.16 -7.24 (m, 1 H), 7.28 (d, J=9 Hz, 1 H), 7.36 - 7.44 (m, 1 H), 7.45 - 7.52 (m, 1 H), 7.57 (d, J=8 Hz, 1 H), 8.02 (dd, J=9, 2 Hz, 1 H), 8.17 (t, J=9 Hz, 2 H), 8.67 (s, 1 H) ppm; MS (DCI/NH3) m/z 371 (M+H)+. Example 39 3-[6-(1H-lndol-3-yl)-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane hemifumarate Example 39A 3-r6-(1H-lndol-3-yl]-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane 3-Quinuclidinol (Aldrich, 254 mg, 2 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1H-indole (Bionet, 458 mg, 2 mmol) at 60°C for 16 hours according to the procedure of Example 7A. The title compound was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H20 (NH4HCO3, 0.1 M, pH=10), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (400 mg, 63%). 1H NMR (MeOH-D4, 300 MHz) 1.50 -1.64 (m, 1 H), 1.71 -1.93 (m, 2 H), 2.00 - 2.15 (m, 1 H), 2.29 - 2.36 (m, 1 H), 2.78 - 3.04 (m, 5 H), 3.43 - 3.55 (m, 1 H), 5.24 - 5.32 (m, 1 H), 7.12 - 7.25 (m, 3 H), 7.42 - 7.48 (m, "1 H), 7.87 (s, 1 H), 8.01 (d, J=9.2 Hz, 1 H), 8.26 - 8.33 (m, 1 H) ppm. MS (DCI/NH3) m/z321(M+H)*. Example 39B 3-[6-(1H-lndol-3-yl)-pvridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane hemifumarate The product of Example 39A (200 mg, 0.63 mmol) was treated with fumaric acid (Aldrich, 73 mg, 0.63 mmol) in EtOAc/MeOH(v.10:1,10 mL) at ambient temperature overnight to give the title compound (247.3 mg, 100%). 1H NMR (MeOH-D4, 300 MHz) 1.76 -1.91 (m, 1 H), 1.92 - 2.14 (m, 2 H), 2.22 - 2.37 (m, 1 H), 2.51 - 2.58 (m, 1 H), 3.16 - 3.39 (m, 5 H), 3.82 (ddd, J=14.0, 8.2,1.9 Hz, 1 H), 5.40 -5.49 (m, 1 H), 6.67 (s, 1 H), 7.12 - 7.26 (m, 3 H), 7.42 - 7.49 (m, 1 H), 7.89 (s, 1 H), 8.05 (d, J=9.5 Hz, 1 H), 8.26 - 8.32 (m, 1 H) ppm. MS (DCI/NH3) m/z 321(M+H)+. Anal. Calculated for C19H2oN4O0.5 C4O4H4-0.35 H2O: C, 65.56; H, 5.95; N, 14.56. ' Found: C, 65.49; H, 6.21; N, 14.34. Example 40 (R)-3-[6-(1 H-lndol-3-yl)pvridazin-3-vloxy]-1 -aza-bicvclor2.2.21octane fumarate The product of Example 4A (127 mg, 1 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of Example 39. The title compound was obtained as solid (208.3 mg, yield, 35%). 1H NMR (MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 - 2.69 (m, 1 H), 3.32 - 3.55 (m, 5 H), 3.98 (dd, J=13.7, 8.3 Hz, 1 H), 5.49 - 5.57 (m, 1 H), 6.71 (s, 4 H), 7.13 - 7.28 (m, 3 H), 7.46 (d, J=7.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z321(M+H)+. Anal. Calculated for C19H20N4O2.1 C4O4H4-0.35 EtOAc: C, 58.14; H, 5.29; N, 9.42. Found: C, 57.91; H, 5.35; N, 9.42. Example 41 (S)-3-[6-(1 H-lndol-3-yl)-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane fumarate The product of Example 13D (127 mg, 1 mmol) was coupled with 3-(6-chloro-pyridazin-3-yl)-1H-indole (Bionet, 229 mg, 1 mmol) according to the procedure of Example 39. The title compound was obtained as solid (239 mg, yield, 39%).1H NMR (MeOH-d4, 300 MHz) 1.90 - 2.24 (m, 3 H), 2.33 - 2.48 (m, 1 H), 2.61 - 2.69 (m, 1 H), 3.33 - 3.55 (m, 5 H), 3.93 - 4.04 (m, 1 H), 5.49 - 5.57 (m, 1 H), 6.72 (s, 4 H), 7.13 -7.28 (m, 3 H), 7.46 (d, J=8.1 Hz, 1 H), 7.90 (s, 1 H), 8.07 (d, J=9.2 Hz, 1 H), 8.30 (d, J=7.1 Hz, 1 H) ppm. MS (DCI/NH3) m/z321(M+H)+. Anal. Calculated for C19H2oN4O2.1 C404H4-0.5 EtOAc: C, 58.06; H, 5,37; N, 9.21 Found: C, 57.81; H, 5.54; N, 9.53. Example 42 (R)3-[6-(2-Methyl-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicvclo[2.2.2]octane trifluoroacetate Example 42A 2-Methyl-5-(4.4.5.5-tetramethvl-[1.3.21diQxaborolan-2-yl)-1H-indole 5-Bromo-2-methyl-1H-indole (Aldrich, 2.1 g, 10 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 3.05 g, 12 mmol) according to the procedure of Example 26A. The title compound was purified by chromatography (120 g SiO2, hexane : EtOAc, 70:30, Rf. 0.8) as a solid (2.57 g, yield, 43%). 1H NMR (300 MHz, CDCI3) 5 1.35 (s, 12 H), 2.40 (s, 3 H), 6.06 - 6.19 (m, 1 H), 7.14 - 7.46 (m, 2 H), 7.64 - 7.93 (m, 1 H) ppm. MS (DCI/NH3): 258 (M+H)+. Example 42B (R)-3-[6-(2-Methyl-1H-indol-5-yl)-pyridazin-3-vloxy]-1-aza-bicvclo[2.2.2]octane trifluoroacetate The product of Example 9A (112 mg, 0.47 mmol) was coupled with the product of Example 42A (165 mg, 0.64 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (43.3 mg, yield, 28%). 1H NMR (MeOH-d4, 300 MHz) 6 1.88 - 2.25 (m, 3 H), 2.33 - 2.50 (m, 4 H), 2.61 - 2.70 (m, 1 H), 3.32 - 3.54 (m, 5 H), 3.98 (dd, J=13.9, 8.5 Hz, 1 H), 5.49 -5.57 (m, 1 H), 6.24 (s, 1 H), 7.31 (d, J=8.8 Hz, 1 H), 7.38 (d, J=8.5 Hz, 1 H), 7.63 (dd, J=8.5, 2.0 Hz, 1 H), 7.99 (d, J=1.4 Hz, 1 H), 8.12 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NHs) m/z 335 (M+H)+. Anal. Calculated for C20H22N4OF3O2-H: C, 57.09; H, 4.96; N, 11.89. Found: C, 57.05; H, 4.71; N, 11.84. Example 43 (3R)-3-(6-Benzo[b]thiophen-5-yl-Pvridazin-3-vloxy)-1-aza-bicvclo[2.2.2]octane trifluoroacetate The product of Example 9A (120 mg, 0.5 mmol) was coupled with 2-(1-benzothiophen-5-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Maybridge, 260 mg, 1.0 mmol) according to the procedure of Example 26B . The title product was purified by preparative HPLC (column: Xterra™ RP-18, 5 urn, 30 x 100 mm. eluting solvent, MeCN / H20 (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) flow rate, 40 mL/min., uv, 254 nm) to provide a solid (157.3 mg, yield, 70%). 1H NMR (300 MHz, CD3OD) 5 1.92 - 2.25 (m, 3 H) 2.35 - 2.49 (m, 1 H) 2.63 - 2.71 (m, 1 H) 3.35 - 3.56 (m, 5 H) 3.95 - 4.06 (m, 1 H) 5.55 - 5.62 (m, 1 H) 7.37 (d, J=9.16 Hz, 1 H) 7.50 (dd, J=5.43, 0.68 Hz, 1 H) 7.68 (d, J=5.43 Hz, 1 H) 7.96 - 8.02 (m, 1 H) 8.05 - 8.10 (m, 1 H) 8.22 (d, J=9.49 Hz, 1 H) 8.45 (d, J=1.70 Hz, 1 H) ppm. MS (DCI/NH3) m/z 338 (M+H)*. Anal. Calculated for C19H19N3OS-CF3CO2H: C, 55.87; H, 4.47; N, 9.31. Found: C, 55.51; H, 4.28; N, 9.12. Example 44 (3R)-3-[6-(1H-lndol-6-yl)-pvridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane trifluoroacetate The product of Example 9A (112 mg, 0.467 mmol) was coupled with indole-6-boronic acid (Frontier, 112 mg, 0.696 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (column: Xterra™ RP-18, 5 urn, 30 x 100 mm; eluting solvent: MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.); flow rate: 40 mL/min.; uv, 254 nm) to provide a solid (133.4 mg, yield, 64%). 1H NMR (300 MHz, CD3OD) 6 1.91 - 2.24 (m, 3 H) 2.35 - 2.48 (m, 1 H) 2.62 - 2.70 (m, 1 H) 3.34 - 3.55 (m, 5 H) 3.99 (dd, J=13J3, 8.31 Hz, 1 H) 5.51 - 5.59 (m, 1 H) 6.51 (d, J=2.03 Hz, 1 H) 7.30 - 7.38 (m, 2 H) 7.58 - 7.64 (m, 1 H) 7.66 - 7.72 (m, 1 H) 8.01 (s, 1 H) 8.15 (d, J=9.49 Hz, 1 H) ppm. MS (DCI/NH3) m/z 321 (M+H)*. Anal. Calculated for C19H20N4O.1CF3CO2H: C, 57.12; H, 4.77; N, 12.57. Found: C, 57.37; H, 4.88; N, 12.38. Example 45 (3R)-3-(6-Benzo[.2.5]oxadiazol-5-vl-pvridazin-3-vloxy)-1-aza-bicvclof2.2.21octane trifluoroacetate The product of Example 9A (122 mg, 0.509 mmol) was coupled with benzo[c][1,2,5]oxadiazol-5-boronic acid (Frontier, 102 mg, 0.622 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (column: Xterra™, RP-18, 5 urn, 30 x 100 mm.; eluting solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.); flow rate: 40 mL/min.; uv, 254 nm) to provide a solid (24.1 mg, yield, 10.4%). 1H NMR (300 MHz, CD3OD) 6 1.93 - 2.26 (m, 3 H) 2.34 - 2.48 (m, 1 H) 2.64 - 2.72 (m, 1 H) 3.35 - 3.57 (m, 5 H) 4.01 (dd, J=14.24, 8.48 Hz, 1 H) 5.59 - 5.66 (m, 1 H) 7.42 (d, J=9.16 Hz, 1 H) 8.08 (dd, J=9.49, 1 .02 Hz, 1 H) 8.33 - 8.40 (m, 2 H) 8.53 (s, 1 H) ppm. MS (DCI/NH3) m/z 324 (M+H)+. Anal. Calculated for C17H17N5O2-1.15CF3CO2H: C, 51.01; H, 4.03; N, 15.41. Found: C, 50.92; H, 3.94; N, 15.19. Example 46 6-{6-[3R)-f1-Aza-bicvclo[2.2.2]oct3-yl)oxy]-pyridazin-3-yl}-chromen-4-one trifluoroacetate The product of Example 9A (72 mg, 0.30 mmol) was coupled with chromone-6-boronic acid pinacol ester(Aldrich, 93.1 mg, 0.342 mmol) in 1,4-dioxane (5.0 ml) and aqueous K2CO3 solution (2M, 1 ml) catalyzed by Pd(PPh3)4 (14.5 mg, 0.0125 mmol) at 80 °C for 16 hours. The title product was purified by preparative HPLC (column, Xterra™ RP-18, 5 Mm, 30 x 100 mm; eluting solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.); flow rate, 40 mL/min.; uv, 254 nm) to provide a solid (90.3 mg, yield, 73.6%). 1H NMR (300 MHz, CD3OD) 6 1 .92 - 2.25 (m, 3 H) 2.34 - 2.49 (m, 1 H) 2.62 - 2.71 (m, 1 H) 3.34 - 3.56 (m, 5 H) 4.00 (dd, J=14.07, 8.31 Hz, 1 H) 5.56 - 5.64 (m, 1 H) 6.44 (d, J=6.10 Hz, 1 H) 7.39 (d, J=9.49 Hz, 1 H) 7.78 (d, J=8.82 Hz, 1 H) 8.20 - 8.28 (m, 2 H) 8.48 (dd, J=8.82, 2.37 Hz, 1 H) 8.74 (d, J=2.03 Hz, 1 H) ppm. MS (DCI/NH3) m/z 350 (M+H)+. Anal. Calculated for C20Hi9N3O3-1.1CF3CO2H: C, 56.16; H, 4.27; N, 8.85. Found: C, 56.27; H, 4.14; N, 8.94. Example 47 (3R)-3-[6-( 2-Chloro-1 H-indol-5-yl)-pvridazin-3-vloxy]-1 -aza-bicyclo[2.2.2]octanehydrochloride Example 47A 5-{6-[(3R)-1 -Aza-bicvclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-indole-1 -carboxylic acid tert-butyl ester Under N2, the solution of the product of Example 9B (3.20 g, 10 mmol) in THF (Aldrich, 100 mL) was treated with di-tert-butyldicarbonate (Aldrch, 3.27 g, 15.0 mmol) with Et3N (2.02 g, 20.0 mmol) in the presence of a catalyst, 4- dimethylaminopyridine (60 mg, 0.5 mmol), at 60 °C for 4 h. The solution was concentrated , and the residue was stirred in iPrOAc (50 ml) overnight to give the title product as white solid (4.08 g, yield, 97%). 1H NMR (300 MHz, CD3OD) 8 ppm 1.43 -1.64 (m, 1 H), 1.69 (s, 9 H), 1.72 -1.94 (m, 2 H), 1.97 - 2.19 (m, 1 H), 2.23 -2.40 (m, 1 H), 2.70 - 3.11 (m, 5 H), 3.38 - 3.58 (m, 1 H), 5.18 - 5.43 (m, 1 H), 6.73 (d, J=3.73 Hz, 1 H), 7.27 (d, J=9.16 Hz, 1 H), 7.69 (d, J=3.73 Hz, 1 H), 7.91 (dd, J=8.82, 1.70 Hz, 1 H), 8.10 (d, J=9.49 Hz, 1 H), 8.16 (d, J=1.70 Hz, 1 H), 8.25 (d, J=8.82 Hz, 1 H) ppm; MS (DCI/NH3) m/z 421 (M+H)+. Example 47B 5-(6-[(3R)-1-Aza-bicvclo[2.2.2]oct-3-vloxv1-pyridazin-3-yl}-2-chloro-indole-1- carboxvlic acid tert-butyl ester The solution of the product of Example 47A (210.0 mg, 0.5 mmol) in anhydrous THF (10 ml) was cooled to -78°C and treated with t-BuOK (Aldrich, 110 mg, 1.0 mmol) and n-BuLi (Aldrich, 1.6 M in hexane, 0.62 mL) for 1 h. Hexachloroethane (Aldrich, 120 mg, 0.5 mmol, in 1 ml of THF) was then added slowly. After the mixture was stirred at -78 °C for additional 1 h, it was quenched with 1 ml of water. The reaction mixture was extracted with EtOAc (2x10 ml). The combined extract was concentrated and the title product was purified by chromatography (Si02) to provide a white solid (110 mg, yield, 62%). 1H NMR (300 MHz, CD3OD) 6 ppm 1.75 - 2.22 (m, 12 H), 2.25 - 2.47 (m, 1 H) ,2.52 - 2.76 (m, 1 H), 3.20-3.40 (m, 5 H), 3.72 - 4.00 (m, 1 H), 5.42 - 5.72 (m, 1 H), 6.58 (d, J=3.05 Hz, 1 H), 7.32 (d, J=2.71 Hz, 1 H), 7.52 (d, J=8.48 Hz, 1 H), 7.76 (d, J=8.48 Hz, 1 H), 8.18 (s, 1 H), 8.31 (s, 1 H) ppm; MS (DCI/NH3) m/z 355, 357 (M+H-Boc)+. Example 47C (3R)-3-{6-(2-Chloro-1 H-indol-5-yl-pvridazin-3-vloxy]-1 -aza- bicvclor2.2.21octane hvdrochloride The product of Example 47B (110 mg, 0.24 mmol) was treated with HCI (Aldrich, 4 M in dioxane, 0.5 mL) in 'PrOH at ambient temperature overnight. The title product was obtained as a yellow solid (50 mg, yield, 53%). 1H NMR (300 MHz, CD3OD) 8 ppm 1.93 - 2.31 (m, 3 H), 2.33 - 2.55 (m, 1 H), 2.65 - 2.81 (m, 1 H), 3.33 - 3.59 (m, 5 H), 3.59 - 3.75 (m, 1 H), 5.38 - 5.77 (m, 1 H), 6.68 (d, J=4.07 Hz, 1 H), 7.43-7.45 (m, 1 H), 7.65 (d, J=8.80 Hz, 1 H), 7.71 - 7.78 (dd, J=8.40, 2.10 Hz, 1 H), 8.28 (d, J=1.36 Hz, 1 H), 8.86 (s, 1 H) ppm; MS (DCI/NH3) m/z 355, 357 (M+H)+. Example 48 (R)-3-[6-(2-Trifluoromethyl-1H-indol-5-yl)-pyridazin-3-vloxy]-1-aza- bicvclo[2.2.21octane Example 48A 5-(4.4.5.5-Tetramethy-[1.3.21dioxaborolan-2-yl)-2-trifluoromethyl-1H-indole 5-Bromo-2-trifluoromethyl-1H-indole (Ref. US 2005043347, 6.05 g, 22.9 mmol) was treated with bis(pinacolato)diboron (7.74 g, 30.5 mmol), with KOAc (8.05 g, 82 mmol) in the presence of PdCl2(dppf)-CH2Cl2 (901 mg, 1.1 mmol) in anhydrous DMF (242 ml) according to the procedure of Example 26A The titled compound was purified by chromatography (SiO2, hexane : EtOAc, 70 : 30, Rf=0.6) as solid (7.83g, yield, 87.9%). 1H NMR (300 MHz, CD3OD) 6 1.36 (s, 12 H), 6.91 (s, 1 H), 7.43 (d, J=8.48 Hz, 1 H), 7.64 (d, J=8.14 Hz, 1 H), 8.11 (s, 1 H) ppm; MS (DCI/NH3): 312 Example 48B f3f?)-3-f6-(2-Trifluoromethvl-1H-indol-5-yl-pvridazin-3-yloxv1-1-aza- bicvclo[2.2.21octane The product of Example 9A (198 mg, 0.826 mmol) was coupled with the product of Example 48A (345 mg, 1.1 1 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (column: Xterra™ RP-18, 5 urn, 30 x 100 mm; eluting solvent, NH4HCO3-NH4OH / H20 (PH=10), (v. 90/10 to 10/90 over 20 min.); flow rate, 40 mL/min.; uv, 254 nm) to provide a solid (79.7 mg, yield, 24.8%). 1H NMR (300 MHz, CD3OD) 5 1.50 - 1.93 (m, 3 H) 1.99 -2.15 (m, 1 H) 2.29 - 2.37 (m, 1 H) 2.78 - 3.05 (m, 5 H) 3.49 (ddd, J=14.83, 8.39, 1 .86 Hz, 1 H) 5.27 - 5.36 (m, 1 H) 7.01 (s, 1 H) 7.27 (d, 7=9.49 Hz, 1 H) 7.59 (d, >8.81 Hz, 1 H) 7.94 (dd, J=8.81, 1.70 Hz, 1 H) 8.11 (d, J=9.15 Hz, 1 H) 8.24 (s, 1 H) ppm. MS (DCI/NH3) m/z 389 (M+Hf. Anal. Calculated for C20Hi9F3N40: C, 61 .85; H, 4.93; N, 14.43. Found: C, 61.62; H, 4.56; N, 13.89. Example 49 -indazol-5-vn-Pvridazin-3-yloxy]-1-1 -aza-bicvclor2.2.21octane fumarate Example 49A 5-(4.4.5.5-tetramethyl-1 .3.2-dioxaborolan-2-yl)-1 H-indazole 5-bromo-1H-indazole (Ref. US 2003199511, 9.45 g, 48 mmol) was treated with bis(pinacolato)diboron(Aldrich, 15.5 g, 61 mmol) according to the procedure of Example 26A. The title product was purified by chromatography (SiO2, hexane : EtOAc, 90 : 10, Rf=0.6) to provide a solid (9.8 g, yield, 84%). 1H NMR (300 MHz, CD3OD) 6 1.36 (s, 12 H), 7.51 (dt, J=8.48, 1.02 Hz, 1 H), 7.73 (dd, J=8.48, 1.02 Hz, 1 H), 8.08 (d, J=1.02 Hz, 1 H), 8.23 (t, J=1.02 Hz, 1 H) ppm. MS (DCI/NH3): m/z 245 Example 49B (3R)-3-[6-MH-indazol-5yl)-pyridazin-3-vloxy]-1-1-aza-bicvclor2.2.2]octane fumarate The product of Example 9A (481 mg, 2.01 mmol) was coupled with the product of Example 49A (968 mg, 3.96 mmol) according to the procedure of Example 26B. The free base of the title product was purified by chromatography (Si02, EtOAc/ MeOH (with 2 v.% NH3-H2O) (385 mg, 1.19 mmol, yield, 59.5% ). It was then treated with fumaric acid (134 mg, 1.2 mmol) in 15 ml EtOAc/EtOH (10:1 v.) at room temperature for 16 hours. The title product was obtained as a solid (414.6 mg, yield, 59.7%). 1H NMR (300 MHz, CD3OD) 6 1.90 - 2.24 (m, 3 H) 2.32 - 2.47 (m, 1 H) 2.61 - 2.70 (m, 1 H) 3.32 - 3.52 (m, 5 H) 3.96 (dd, J=13.73, 8.31 Hz, 1 H) 5.53 -5.60 (m, 1 H) 6.69 (s, 2 H) 7.36 (d, J=9.49 Hz, 1 H) 7.69 (d, J=8.82 Hz, 1 H) 8.08 (dd, J=8.82, 1.70 Hz, 1 H) 8.16 - 8.23 (m, 2 H) 8.38 (s, 1 H) ppm. MS (DCI/NH3) m/z 322 (M+H)+. Anal. Calculated for C18H19N5O.14C4H4O.6H2O: C, 57.30; H, 5.26; N, 14.16. Found: C, 57.24; H, 5.08; N, 14.24. °C. Seven log-dilution concentrations of each compound were tested in duplicate. Non-specific binding was determined in the presence of 10µM (-)-nicotine. Bound radioactivity was isolated by vacuum filtration onto prewetted glass fiber filter plates (Millipore, Bedford, MA) using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 ml of ice-cold BSS buffer (120 mM NaCI/5 mM KCI/2 mM CaCI2/2 mM MgCI2). Packard M5croScint-20® scintillation cocktail (40 uL) was added to each well and radioactivity determined using a Packard TopCount® instrument. The IC50 values were determined by nonlinear regression in Microsoft Excel® software. KI values were calculated from the ICsoS using the Cheng-Prusoff equation, where KI = IC50/1+[Ligand]/KD]. r3H1-Methvllvcaconitine (MLA) binding Binding conditions were similar to those for [3H]-cytisine binding. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI, 5 mM KCI, 2 mM CaCI2, 2 mM MgCI2, and 50 mM Tris-CI, pH 7.4, 22 °C). Samples containing 100-200 ug of protein, 5 nM [3H]-MLA (25 Ci/mmol; Perkin Elmer/NEN Life Science Products, Boston, MA) and 0.1% bovine serum albumin (BSA, Millipore, Bedford, MA) were incubated in a final volume of 500 uL for 60 minutes at 22 °C. Seven log-dilution concentrations of each compound were tested in duplicate. Non-specific binding was determined in the presence of 10 uM MLA. Bound radioactivity was isolated by vacuum filtration onto glass fiber filter plates prewetted with 2% BSA using a 96-well filtration apparatus (Packard Instruments, Meriden, CT) and were then rapidly rinsed with 2 ml of ice-cold BSS. Packard MicroScint-20® scintillation cocktail (40 uL) was added to each well and radioactivity was determined using a Packard TopCount® instrument. The IC50 values were determined by nonlinear regression in Microsoft Excel® software. KI values were calculated from the IC50S using the Cheng-Prusoff equation, where KI = IC5o/1+[Ligand]/KD]. Compounds of the invention had KI values of from about 1 nanomolar to about 10 micromolar when tested by the MLA assay, many having a KI of less than 1 micromolar. [3H]-Cytisine binding values of compounds of the invention ranged from Example 50 (3S)-3-r6-(1H-lndazol-5-yl)-pyridazin-3-vloxy]-1-1-aza-bicvclor2.2.21octane trifluoroacetate The product of Example 30A (132 mg, 0.549 mmol) was the product of Example 49A (325 mg, 1.33 mmol) according to the procedure of Example 26B. The i title product was purified by preparative HPLC (column: Xterra™, RP-18, 5 urn, 30 x 100 mm; eluting solvent, MeCN / H2O (with 0.1 % v. TFA), (v. 90/10 to 10/90 over 20 min.); flow rate, 40 mL/min.; uv, 254 nm) to provide a solid (115.3 mg, yield, 45.8%). 1H NMR (300 MHz, CD3OD) 5 1.92 - 2.25 (m, 3 H) 2.34 - 2.49 (m, 1 H) 2.63 - 2.72 (m, 1 H) 3.34 - 3.57 (m, 5 H) 3.99 (dd, J=13.90, 8.14 Hz, 1 H) 5.54 - 5.61 (m, 1 H) 7.36 (d, J=9.49 Hz, 1 H) 7.69 (d, J=8.82 Hz, 1 H) 8.08 (dd, J=8.82,1.70 Hz, 1 H) 8.16 - 8.23 (m, 2 H) 8.38 (dd, J=1.53, 0.85 Hz, 1 H) ppm. MS (DCI/NH3) m/z 322 (M+H)+. Anal. Calculated for C18H19N50-1.2 CF3CO2H: C, 53.47; H, 4.44; N, 15.28. Found: C, 53.67; H, 3.99; N, 15.40. Example 51 DETERMINATION OF BIOLOGICAL ACTIVITY To determine the effectiveness of representative compounds of this invention as a? nAChRs, the compounds of the invention were evaluated according to the [3H]-methyllycaconitine (MLA) binding assay and considering the [3H]-cytisine binding assay, which were performed as described below. [3H1-Cytisine binding Binding conditions were modified from the procedures described in Pabreza LA, Dhawan, S, Kellar KJ, [3H]-Cytisine Binding to Nicotinic Cholinergic Receptors in Brain, Mol. Pharm. 39: 9-12,1991. Membrane enriched fractions from rat brain minus cerebellum (ABS Inc., Wilmington, DE) were slowly thawed at 4 °C, washed and resuspended in 30 volumes of BSS-Tris buffer (120 mM NaCI/5 mM KCI/2 mM CaCI2/2 mM MgCI2/50 mM Tris-CI, pH 7.4, 4 °C). Samples containing 100-200 pg of protein and 0.75 nM [3H]-cytisine (30 Ci/mmol; Perkin Elmer/NEN Life Science Products, Boston, MA) were incubated in a final volume of 500 µL for 75 minutes at 4 about 50 nanomolar to at least 100 micromolar. The determination of preferred compounds typically considered the KI value as measured by MLA assay in view of the KI value as measured by [3H]-cytisine binding, such that in the formula D = KISH-cytisine /Kj MLA, D is about 50. Preferred compounds typically exhibited greater potency at α7 receptors compared to α4ß2 receptors. Compounds of the invention are α7 nAChRs ligands that modulate function of α7 nAChRs by altering the activity of the receptor. The compounds can be inverse agonists that inhibit the basal activity of the receptor or antagonists that completely block the action of receptor-activating agonists. The compounds also can be partial agonists that partially block or partially activate the α7 nAChR receptor or agonists that activate the receptor. Some compounds of the invention also have been evaluated for binding to the hERG ion channel. Blockade of the hERG ion channel has been associated with interference of heart muscle repolarization, which presents a risk for cardiovascular toxicity. r3H1-Dofetilide binding Membrane preparations from HERG-transfected HEK cells were obtained as described in Diaz et al (2004). Membrane aliquots were thawed and homogenized again in a glass Dounce homogenizer (approximately 10 passes). Test compounds were diluted (6 concentrations at half-log intervals) from DMSO stock solutions in assay buffer (135 mM NaCI, 5 mM KCI, 0.8 mM MgCI2,10 mM HEPES, 10 mM glucose, 1 mM EGTA, 0.01% BSA, pH 7.4), and tested in duplicate at each concentration. The following were added to each 200 til well of a 96-well polystyrene plate (Packard Optiplate, cat. # 6005290): 20 n-l of assay binding buffer (for total bounds), or 1 µM astemizole (for non-specific bounds), or test compound, 50 yl of [3H]-dofetilide, and 130 µl of membrane homogenate (final protein concentration = 30 tig per well). The plates were incubated at room temperature for 45 m, aspirated onto GF/B filter plates, and washed with 2 ml of cold wash buffer. The radioactivity was counted in a Packard Topcount Scintillation Counter after addition of 50 jjJ of scintillant (Packard Microscint-20, cat. # 6013621). The data were analyzed with a four-parameter logistic equation (PRISM™, Graphpad or Assay Explorer™, MDL). Kj values were derived by means of the Cheng and Prusoff (1973) equation (K| = ICso/1 + [Iigand]/Kd) using Kd values for [3H]-dofetilide obtained from previously performed saturation assays (Diaz et al., 2004). For drugs that failed to displace more than 50% of labeled dofetilide at the highest concentration tested, KI values were reported as "greater than" that concentration. Each KI represents an average of at least two independent determinations. Thus, binding affinities to the hERG channel were expressed in KI value, i.e. KI hERG. Compounds of the invention exhibiting selectivity for a? receptor binding (Ki MLA) compared to hERG binding were considered to demonstrate a better cardiovascular risk profile. In particular, higher levels of binding selectivity, as represented by the ratio: KIHERG/KIMLA provide an indication of the therapeutic benefit versus the cardiovascular risk for these compounds. Accordingly, the evaluation of the effectiveness ofα7 nAChRs relative to binding affinities to the hERG channel is an effective manner for determining compounds demonstrating a beneficial safety and efficacy profile more suitable for pharmaceutical administration. Compounds of the invention, and particularly those of the preferred embodiments, demonstrate a beneficial cardiovascular risk profile. To better characterize such properties, compounds of the invention were assessed relative to variousα7 nAChRs. Such α7 nAChRs compounds were prepared according to the following additional Examples. Example Compound A (R)-3-(6-Naphthalen-2-yl-Dvridazin-3-vloxy)-1-aza-bicvclor2.2.21octane trifluoroacetate The product of Example 9A (120 mg, 0.5 mmol) was coupled with 2-naphthaleneboronic acid (Aldrich, 172 mg, 1.0 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) flow rate, 75 mL/min., uv, 250 nm) as solid (75.1 mg, yield, 34%). 1H NMR (MeOH-d4l 300 MHz) 6 1.91 - 2.27 (m, 3 H), 2.33 - 2.51 (m, 1 H), 2.62 - 2.72 (m, 1 H), 3.34 - 3.58 (m, 5 H), 4.01 (dd, J=14.1, 8.0 Hz, 1 H), 5.54 - 5.65 (m, 1 H), 7.40 (d, J=9.2 Hz, 1 H), 7.52 - 7.61 (m, 2 H), 7.88 - 8.06 (m, 3 H), 8.10 - 8.19 (m, 1 H), 8.30 (d, J=9.2 Hz, 1 H), 8.47 (s, 1 H) ppm. MS (DCI/NH3) m/z 332 (M+H)*. Anal. Calculated for C21N3OC2F3O2H: C, 62.02; H, 4.98; N, 9.43. Found: C, 61.67; H, 4.73; N, 9.30. Example Compound B (R)-3-r6-fBenzofuran-5-yl)-pvridazin-3-vloxv]-1-aza-bicvclor2.2.21octane trifluoroacetate The product of Example 9A (120 mg, 0.5 mmol) was coupled with benzofuran-5-boronic acid (Apollo, 81 mg, 0.5 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H20 (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) flow rate, 75 mL/min., uv, 250 nm) as solid (88.3 mg, yield, 40%). 1H NMR (MeOH-d4, 300 MHz) 6 1.90 - 2.26 (m, 3 H), 2.33 - 2.50 (m, 1 H), 2.60 - 2.72 (m, 1 H), 3.34 - 3.56 (m, 5 H), 3.92 - 4.06 (m, 1 H), 5.51 - 5.63 (m, 1 H), 6.96 (d, J=1.4 Hz, 1 H), 7.31 - 7.39 (m, 1 H) 7.65 (d, J=8.8 Hz, 1 H) 7.85 (d, J=2.0 Hz, 1 H) 7.94 (dd, J=8.6,1.9 Hz, 1 H) 8.17 (d, J=9.5 Hz, 1 H) 8.22 (d, J=1.4 Hz, 1 H) ppm. MS (DCI/NH3) m/z 322 (M+H)+. Anal. Calculated for C19H19N3O2.O5C2F3O2H: C, 57.45; H, 4.58; N, 9.53. Found: C, 57.27; H, 4.52; N, 9.30. Example Compound C (R)-3-[6-(Benzofuran-2-yl)-Dvridazin-3-vloxy]-1-aza-bicvclor2.2.21octane trifluoroacetate . The product of Example 9A (120 mg, 0.5 mmol) was coupled with 2-benzofuranboronic acid (Aldrich, 97 mg, 0.6 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 Mm, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) as solid (58.3 mg, yield, 24%). 1H NMR (MeOH-d4, 300 MHz) 5 1.90 - 2.26 (m, 3 H), 2.34 - 2.49 (m, 1 H), 2.62 - 2.71 (m, 1 H), 3.34 - 3.57 (m, 5 H), 4.00 (dd, J=14.2, 8.1 Hz, 1 H), 5.55 -5.63 (m, 1 H), 7.27 - 7.46 (m, 3 H), 7.56 - 7.75 (m, 3 H), 8.23 (d, J=9.5 Hz, 1 H) ppm. Mb (DCl/NH3) m/z 322 (M+H)+. Anal. Calculated for C19H19N302-1.5C2F3O2H: C, 53.66; H, 4.20; N, 8.53. Found: C, 53.79; H, 4.47; N, 8.14. Example Compound D -f6-(1 H-lnden-5-yl)-pvridazin-3-vloxy]-1 -aza-bicvclor2.2.21octane trifluoroacetate Example Compound D1 2-f 1 H-lnden-5-yl)-4.4.5.5-tetramethyl-[1, .3.21dioxaborolane 5-Bromo-1H-indene (Maybridge, 1.0 g, 5.1 mmol) was coupled with bis(pinacolato)diboron (Aldrich, 1.6 g, 6.3 mmol) according to the procedure of Example 26A. The title compound was purified by chromatography (120 g SiO2, hexane : EtOAc, 40:60, Rf. 0.9) as a solid (0.70 g, yield, 57%). 1H NMR (300 MHz, CDCI 3) 5 1 .35 (s, 12 H), 3.40 (s, 2 H), 6.50 - 7.89 (m, 5 H) ppm. MS (DCI/NH3): 260 (M+NH4)*. Example Compound D2 fffl-3-r6-f1H-lnden-5-vn-pvridazin-3-vloxv1-1-aza-bicvclof2.2.21octane trifluoroacetate The product of Example 9A (120 mg, 0.5 mmol) was coupled with Compound D1 (242 mg, 1.0 mmol) according to the procedure of Example 26B. The title product was purified by preparative HPLC (Xterra™, column, Xterra RP-18, 5 urn, 30 x 100 mm. Eluting Solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) flow rate, 75 mL/min., uv, 250 nm) as solid (102.6 mg, yield, 47%). 1H NMR (MeOH-d4, 300 MHz) 5 1.90 - 2.26 (m, 3 H), 2.33 - 2.49 (m, 1 H), 2.61 - 2.71 (m, 1 H), 3.33 - 3.56 (m, 7 H), 3.99 (dd, ,7=13.9, 8.1 Hz, 1 H), 5.51 - 5.61 (m, 1 H), 6.66 -6.76 (m, 1 H), 6.93 - 7.02 (m, 1 H), 7.34 (dd, J=9.3, 3.2 Hz, 1 H), 7.54 (d, J=7.80 Hz, 0.5 H), 7.62 (d, J=7.80 Hz, 0.5 H), 7.78 (dd, J=7.80, 1.36 Hz, 0.5 H), 7.87 (dd, J=8.14, 1.70 Hz, 0.5 H), 7.98 (d, J=1.36 Hz, 0.5 H), 8.06-8.10 (m, 0.5 H), 8.14 (d, J=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 320 (M+Hf. Anal. Calculated for C2oH2iN3O1.05C2F3O2H: C, 60.45; H, 5.06; N, 9.57. Found: C, 60.26; H, 5.01; N, 9.38. Example Compound E (RV3-(6-lndan-5-vl-Dvridazin-3-vloxv)-1-aza-bicvclor2.2.21octane trifluoroacetate Compound D2 (57.8 mg, 0.13 mmol) was dissolved in ethanol (10 ml), degassed and then hydrogenated under the catalysis of Pd/C (10%, 10 mg) with H2 at room temperature for 1 hour. After the reaction went to completion, the reaction mixture was carefully filtered through diatomaceous earth to remove catalyst. The ethanol solution was concentrated. The title compound was purified by preparative RP HPLC (Symmetry® C-8, 7µm, 40 x 100 mm; Eluting Solvent, MeCN / H2O (with 0.1% v. TFA), (v. 90/10 to 10/90 over 20 min.) Flow rate, 75 mL/min., uv, 250 nm) to give the title compound as solid (22.4 mg, yield, 38%). 1H NMR (MeOH-d4, 300 MHz) 6 1.92 - 2.22 (m, 5 H), 2.34 - 2.45 (m, 1 H), 2.62 - 2.68 (m, 1 H), 2.94 - 3.04 (m, 4 H), 3.33 - 3.53 (m, 5 H), 3.93 - 4.02 (m, 1 H), 5.52 - 5.58 (m, 1 H), 7.30 - 7.39 (m, 2 H), 7.71 (d, J=7.9 Hz, 1 H), 7.80 (s, 1 H), 8.08 (d, 7=9.2 Hz, 1 H) ppm. MS (DCI/NH3) m/z 322 (M+H)+. Anal. Calculated for C2oH23N3O-1.13C2F302H: C, 59.38; H, 5.40; N.9.33. Found: C, 59.41; H, 5.51; N, 9.22. Representative compounds, including among them some compounds of the invention, were evaluated for determining such safety and efficacy relative to prepared Compounds A-E. The results are summarized below in Table 1. (Table Removed) Compounds of the invention typically exhibited KIERG/KIMLA selectivity ratios greater than 200, demonstrating a beneficial cardiovascular risk profile for α7 receptor ligands. Preferred compounds of the invention demonstrated Ki hERG/KI MLA selectivity ratios greater than 1000. It is understood that the foregoing detailed description and accompanying examples are merely illustrative and are not to be taken as limitations upon the scope of the invention, which is defined solely by the appended claims and their equivalents. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications, including without limitation those relating to the chemical structures, substituents, derivatives, intermediates, syntheses, formulations and/or methods of use of the invention, may be made without departing from the spirit and scope thereof. WHAT IS CLAIMED IS: 1. A compound of the formula (I)(Formula Removed) (I) or a pharmaceutically acceptable salt, amide, or prodrug thereof, wherein: nisO, 1,or2; A is N or N+-O-; X is selected from the group consisting of O, S, and -N(R1)-; Ar1 is a 6-membered aromatic ring containing 0, 1, 2, 3, or 4 nitrogen atoms, wherein Ar1 is substituted with 0, 1 , 2, 3, or 4 alkyl groups; Ar2 is a group of the formula: (Formula Removed)Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z1, Z2, Z3, and Z4 is C; . Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C; Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are independently selected from the group consisting of C and -C(R3°); provided that one of Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 is C and the group of formula (c) is attached to Ar1 through the C atom; Y1 at each occurrence is independently selected from the group consisting of • O, S, -N(R2), -C(R3), and -C(R3)(R3a); Y2 is selected from the group consisting of -N(R2), C(=O), -C(R3), and -C(R3)(R3a); Y3 is selected from the group consisting of -N(R2), -C(R3), and -C(R3)(R3a); provided that zero or one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a); wherein when one of Y1, Y2, and Y3 is -C(R3) in a group of formula (a), then Z1, Z2, Z3, and Z4 are each -C(R3b) and the group of formula (a) is attached to Ar1 through the C atom of -C(R3) of Y1, Y2, or Y3; and also when one of Z1, Z2, Z3, and Z4 is C, then Y1, Y2 and Y3 are other than -C(R3) and the group of formula (a) is attached to Ar1 through the C atom of Z1, Z2, Z3, or Z4; Y2a and Y3a are independently selected from the group consisting of N, C and -C(R3a); provided that when Y1 is -C(R3) in a group of formula (b), Y2a and Y3a are selected from the group consisting of N and -C(R3a), and when one of Y2a and Y3a is C, then Y1 in a group of formula (b) is 0, S, -N(R2), or -C(R3)(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y1 in a group of formula (b) is selected from the group consisting of O, S, -N(R2), and -C(R3)(R3a); Y2a and Y3a are each independently selected from the group consisting of N and -C(R3a); and the group of formula (b) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8 ; and also wherein when Y1 in a group of formula (b) is -C(R3) or one of Y2a and Y3a is C, then Z5, Z6, Z7, and Z8 are each -C(R3b) and the group of formula (b) is attached to Ar1 through the C atom of -C(R3) of Y1 in the group of formula (b) or through the C atom R1 and R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl; R3 and R3a at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, and -alkyl-NR5R6; R3b and R3c at each occurrence are each independently selected from the group consisting of hydrogen, halogen, alkyl, aryl, -OR4, -NR5R6, -alkyl-OR4, -alkyl-NR5R6, and -SCN; R4 is selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, and arylcarbonyl; R5 and R6 at each occurrence are each independently selected from the group consisting of hydrogen, alkyl, aryl, alkylcarbonyl, alkoxycarbonyl, aryloxycarbonyl, and arylcarbonyl, provided that at least one of R5 and R6 is hydrogen or alkyl; and R8 is selected from the group consisting of hydrogen and alkyl. 2. The compound of claim 1, wherein Ar1 is a group of the formula: 4. The compound of claim 1, wherein Ar2 is selected from the group consisting of: (Formula Removed)wherein: Z1, Z2, Z3, and Z4 are independently selected from the group consisting of C and -C(R3b); provided that one of Z1, Z2, Z3, and Z4 is C and formula (ix) is attached to Ar1 through the C atom of Z1, Z2, Z3, and Z4; Y1 is selected from the group consisting of O, S, and -C(R3)(R3a); Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of 2s, Z6, Z7, and Z8 is C; Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8 ; and also wherein when one of Y2a and Y3a is C in the group of formulae (i)-(vii), then Z5, Z6, Z7, and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar1 through the C atom of Y^orY^and R2, R3, R3a, R3b, R8, Z9, Z10, Z11, Z12, Z13, Z14, Z15, and Z16 are as defined in claim 1 . 5. The compound of claim 1 , wherein A is N; X is O; n is 1 ; Ar1 is a group of formula: (Formula Removed) and Ar2 is a group of formula: (Formula Removed) R2 at each occurrence are each independently selected from the group consisting of hydrogen and alkyl; R10 at each occurrence is independently selected from the group consisting of hydrogen and alkyl; Z5, Z6, Z7, and Z8 are independently selected from the group consisting of C and -C(R3b); provided that zero or one of Z5, Z6, Z7, and Z8 is C; and Y2a and Y3a are independently selected from the group consisting of C and -C(R3a); wherein when one of Z5, Z6, Z7, and Z8 is C, then Y2a and Y3a in the group of formulae (i)-(vii) are each -C(R3a); and each of the group of formulae (i)-(vii) is attached to Ar1 through the C of Z5, Z6, Z7, or Z8 ; and also wherein when one of Y2a and Y3a is C in the group of formulae (i)-(vii), then Z5, Z6, Z7, and Z8 are each -C(R3b) and each of the group of formulae (i)-(vii) is attached to Ar1 through the C atom of 6. The compound of claim 5, wherein Ar1 is (Formula Removed) 7. The compound of claim 5, wherein Ar1 is 8. (Formula Removed) The compound of claim 7, wherein Z7 in a group of formula (i) is C and the group of formula (i) is attached to Ar1 via the C atom represented by Z7. 9. The compound of claim 7, wherein Z6 in a group of formula (i) is C and the group of formula (i) is attached to Ar1 via the C atom represented by Z6. 10. The compound of claim 7, wherein Y2a in a group of formula (i) is C and the group of formula (i) is attached to Ar1 via the C atom represented by Y2a. 11. The compound of claim 7, wherein Y3a in a group of formula (i) is C and the group of formula (i) is attached to Ar1 via the C atom represented by Y3a. 12. The compound of claim 5, wherein Ar1 is (Formula Removed) 13. The compound of claim 1, or a pharmaceutically acceptable salt, amide, or prodrug thereof, selected from the group consisting of: 3-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 4-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 5-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 5-{4-[(3R)-1 -azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1 H-indole; 6-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 2-[4-(1 -azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1 H-indole; 5-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1H-indole; 4-[6-(1-azabicyclo[2.2.2]oct-3-yloxy)pyridazin-3-yl]-1 H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1 H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-3-methyl-1 H-indole; 5-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1 H-indole; 4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole; 5-{2-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole; 5-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-3-methyl-1H-indazole; 6-[4-(1-azabicyclo[2.2.2]oct-3-yloxy)phenyl]-1,3-benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-thiocyanato-1,3- benzothiazol-2-amine; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-4-bromo-1,3-benzothiazol-2- amine; N-[4-(3-methyl-1H-indazol-5-yl)phenyl]quinuclidin-3-amine; (R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (R)-3-[6-(1 -methyl-1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}- dimethyl-amine; (R)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane1-oxide; 6-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-benzothiazol-2- ylamine; (3R)-3-[6-(3-bromo-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza- bicyclo[2.2.2]octane; 5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro-indol-2- one; 5-{6-[(3R)-1 -oxy-1 -aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- indol-2-one; 5-{6-[(3R)-1-aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- benzoimidazol-2-one; (R)-3-[6-(1 H-benzoimidazol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (S)-3-[6-(1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane; (3R)-3-[5-(1 H-indol-4-yl)-pyrimidin-2-yloxy]-1 -aza-bicyclo[2.2.2]octane 1 - oxide; (3R)-3-(5-benzooxazol-5-yl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane; (3R)-3-[5-(2-methyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (3R)-3-[5-(2-ethyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (3R)-3-[5-(2-phenyl-benzooxazol-5-yl)-pyrimidin-2-yloxy]-1-aza- bicyclo[2.2.2]octane; (R)-5-[2-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyrimidin-5-yl]-3H-benzooxazol-2- one; (R)-3-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-9H-carbazoIe; 3-[6-(1H-indol-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (R)-3-[6-(1H-indo!-3-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (S)-3-[6-(1H-indol-3-yl)-pyridazin-3-yIoxy]-1-aza-bicyclo[2.2.2]octane; (3R)-3-(6-benzo[b]thiophen-5-yl-pyridazin-3-yloxy)-1-aza-bicyclo[2.2.2]octane; (3R)-3-[6-(1H-indol-6-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane; (3R)-3-(6-benzo[1,2,5]oxadiazol-5-yl-pyridazin-3-yloxy)-1-aza- bicyclo[2.2.2]octane; 6-{6-[(3f?)-(1-aza-bicyclo[2.2.2]oct-3-yl)oxy]-pyridazin-3-yl}-chromen-4-one; (3R)-3-[6-(2-chloro-1 H-indol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (3R)-3-[6-(2-trifluoromethyl-1H-indol-5-yl)-pyridazin-3-yloxy]-1-aza bicyclo[2.2.2]octane; (3R)-3-[6-(1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; and (3S)-3-[6-(1H-indazol-5-yl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane. 14. The compound of claim 1, or a pharmaceutically acceptable salt, amide, or prodrug thereof, selected from the group consisting of: 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl}-1H-indole; 5-{6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazln-3-yl}-3-methyl-1H-indole; 4-{2-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyrimidin-5-yl}-1H-indole; 6-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]phenyl}-1,3-benzothiazol-2-amine; (R)-3-[6-(3-methyl-1 H-indazol-5-yl)-pyridazin-3-yloxy]-1 -aza- bicyclo[2.2.2]octane; (R)-{5-[6-(1-aza-bicyclo[2.2.2]oct-3-yloxy)-pyridazin-3-yl]-1H-indol-3-ylmethyl}- dimethyl-amine; 5-{6-[(3R)-1 -oxy-1 -aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-1,3-dihydro- indol-2-one; 5-{6-[(3S)-1 -azabicyclo[2.2.2]oct-3-y!oxy]pyridazln-3-yl}-1 H-indole or (S)-3-[6-(1 H-indol-3-yl)-pyridazin-3-yloxy]-1 -aza-bicyclo[2.2.2]octane; and (R)-3-[5-(1H-indol-5-yl)-pyridin-2-yloxy]-1-aza-bicyclo[2.2.2]octane. 1 5. The compound of claim 1 , wherein the compound is 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl)-1H-indole, or a pharmaceutically acceptable salt, amide, or prodrug thereof. 16. The compound of claim 1 , wherein the compound demonstrated Kj hERG/Ki MLA selectivity ratios greater than 1000 when measured according to a [3H]- methyllycaconitine (MLA) binding assay and a 3H-dofetilide assay. 17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier. 18. A method of selectively modulating the effects of oc7 nicotinic acetylcholine receptors in a mammal comprising administering an effective amount of a compound of claim 1 . 19. A method of treating or preventing a condition or disorder selected from the group consisting of attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, inflammatory pain, neuropathic pain, infertility, need for new blood vessel growth associated with wound healing, need for new blood vessel growth associated with vascularization of skin grafts, and lack of circulation, more particularly circulation around a vascular occlusion, comprising the step of administering a compound of claim 1 . 20. The method according to claim 1 , wherein the condition or disorder is selected from the group consisting of a cognitive disorder, neurodegeneration, and schizophrenia. 21. The method according to claim 1, further comprising administering a compound of claim 1 in combination with an atypical antipsychotic.